Ratifi English Iniciar sesión
Ratifi

Proyectos federales de Congress.gov. Proyectos estatales de Open States.

HB 2752Sesión 2025-2026

Setting standards for patient and caregiver identification cards to ensure legal access to medical cannabis, establishing the Kansas medical cannabis agency within the department of health and environment and removing cannabis from the Kansas uniform controlled substances act.

As Introduced

El texto subrayado se agregaría a la ley vigente. El texto tachado se eliminaría.

Skip to main content Kansas Legislature kslegislature.gov menu Home House account_balanceAbout the House groupsRepresentatives campaignEvents chairSeating Chart auto_storiesJournals & Calendars manage_accountsChief Clerk of the House gavelRules Senate account_balanceAbout the Senate groupsSenators campaignEvents assignment_indAppointments chairSeating Chart auto_storiesJournals & Calendars manage_accountsSecretary of the Senate gavelRules Committees groupsCommittees eventHearing Schedule handshakeConference Committee Schedule Measures & Laws gavelAll Measures account_balanceHouse Measures account_balanceSenate Measures account_balanceVotes topicSubject Index summarizeReports menu_bookStatutes schoolHow a Bill Becomes Law menu_bookLegislative Procedure Manual Today campaignLive Floor Activity videocamHouse Video videocamSenate Video live_tvStatehouse Live & Archive smart_displayYouTube Channel Resources Archive Search description Go to bill or resolution arrow_forward A− A+ search Search bills, resolutions, and statutes help

Keywords
Enter any words to search bills, statutes, and documents.
water quality funding

Bill or Resolution Number
Type a number and press Enter to go directly to the detail page.
HB 2590 SCR 1611

Statute Number
68-102 72-3715

Exact Phrase
Wrap your query in quotes.
“rules of evidence”

Document Type
Prefix with a type to narrow results.
testimony: HB 2513 minutes: budget

    Searching…

    No results found.

    search Search bills, resolutions, and statutes Home House About the House Representatives Events Seating Chart Journals & Calendars Chief Clerk of the House Rules Senate About the Senate Senators Events Appointments Seating Chart Journals & Calendars Secretary of the Senate Rules Committees All Committees Hearing Schedule Conference Committee Schedule Measures & Laws All Measures House Measures Senate Measures Votes Subject Index Reports Statutes How a Bill Becomes Law Legislative Procedure Manual Resources Today Live Floor Activity House Video Senate Video Statehouse Live & Archive YouTube Channel Archive Search
    1. HB 2752›
    2. HB 2752 — As Introduced

    Kansas Legislature

    HB 2752 — As Introduced

    picture_as_pdf Download PDF Session of 2026HOUSE BILL No. 2752By Committee on Health and Human ServicesRequested by Representative Fairchild2-61AN ACT concerning health and healthcare; establishing the Kansas health 2freedom act; setting standards for patient and caregiver identification 3cards to ensure legal access to medical cannabis; requiring medical 4providers to certify patients for medical cannabis use; protecting 5patients' rights, including firearm ownership and non-disqualification 6from medical care; establishing the Kansas medical cannabis agency 7within the department of health and environment; creating a medical 8cannabis tax fund for research and public health initiatives; ensuring 9confidentiality of patient records; authorizing the expungement of 10certain cannabis-related convictions; sealing of records related to 11decriminalized offenses; removing cannabis from the Kansas uniform 12controlled substances act; amending K.S.A. 21-5706 and 21-5709 and 13K.S.A. 2025 Supp. 21-5701, 21-5705, 65-4101 and 65-4105 and 14repealing the existing sections.1516WHEREAS, findings of the United States department of justice, drug 17enforcement administration, in the matter of docket no. 86‐22, marijuana 18rescheduling petition, opinion and recommended ruling, finding of fact, 19conclusions of law and decision of administrative law Judge Francis L. 20Young stated, "Marijuana, in its natural form, is one of the safest 21therapeutically active substances known to man. By any measure of 22rational analysis marijuana can be safely used within a supervised routine 23of medical care."; and24WHEREAS, The United States drug enforcement administration 25proposed to change the status of cannabis under the controlled substances 26act by moving it from schedule I to the less restrictive schedule III; and27WHEREAS, Congress has enacted appropriations legislation 28prohibiting the United States department of justice from expending 29appropriated funds to prevent states from implementing their own medical 30cannabis law and issued guidance to United States attorneys indicating that 31enforcement of the controlled substances act is not a priority when 32individual patients and their medical care providers are in compliance with 33state law and that federal prosecutors should defer to state and local 34enforcement so long as a viable state regulatory scheme is in place; and35WHEREAS, Forty states, three territories and the district of Columbia 1allow the medical use of cannabis products; and 2WHEREAS, More than 30 years of state-level policies provide a guide 3related to the medical use of cannabis; and4WHEREAS, The American herbal pharmacopoeia and the American 5herbal products association have developed qualitative standards for the 6use of cannabis as a botanical medicine; and published a cannabis 7monograph providing standards for its identity, purity, quality and 8botanical properties; and9WHEREAS, The national institute of standards and technology and the 10United States department of commerce have developed an integrated 11measurement services program for forensic and cannabis testing 12laboratories to help ensure the quality of routine analysis throughout the 13cannabis industry; and14WHEREAS, Accredited educational curricula concerning the medical 15use of cannabis have been established, which meet continuing medical 16education requirements for practicing physicians; and17WHEREAS, President Donald J. Trump signed an executive order on 18December 18, 2025, urging the United States health and human services 19agency, department of justice and affiliated agencies to complete the 20rescheduling process of transitioning cannabis from schedule I to schedule 21III under the controlled substances act, acknowledging generations of 22evidence proving therapeutic benefits of plant constituents and citing 23burdens on industry businesses and investors and limitations against 24research and development.25Now, therefore:26Be it enacted by the Legislature of the State of Kansas:27New Section 1. (a) Sections 1 through 10, and amendments thereto, 28shall be known and may be cited as the Kansas health freedom act.29(b) The legislature of the state of Kansas declares that the Kansas 30health freedom act is enacted pursuant to the police power of the state to 31protect the health of Kansas citizens and that such police power is reserved 32to the state of Kansas and its people under the 10th amendment to the 33Constitution of the United States.34New Sec. 2. As used in this act, unless the context requires otherwise:35(a) "Agency" means the Kansas medical cannabis agency.36(b) "Batch number" means a unique numeric or alphanumeric 37identifier assigned prior to testing to allow inventory tracking and 38traceability.39(c) (1) "Cannabis" or "marijuana" means all parts of all varieties of 40the plant cannabis, whether growing or not, the seeds thereof, the resin 41extracted from any part of the plant and every compound, manufacture, 42salt, derivative, mixture or preparation of the plant, its seeds or resin.43(2) "Cannabis" or "marijuana" does not include the mature stalks of 1the plant, fiber produced from the stalks, oil or cake made from the seeds 2of the plant, any other compound, manufacture, salt, derivative, mixture or 3preparation of the mature stalks, except the resin extracted therefrom, 4fiber, oil or cake or the sterilized seed of the plant that is incapable of 5germination.6(d) "Cannabinoid" means any of the chemical compounds that are 7active principles of cannabis.8(e) (1) "Caregiver" means the individual or entity, designated by a 9patient with an identification card, that is able to cultivate a patient's 10medical cannabis or purchase medical cannabis on the behalf of such 11patient, who has consistently assumed responsibility for the housing, 12health or safety of that patient or person and may include any of the 13following:14(A) A licensed clinic, a licensed state governmental institution clinic, 15a licensed health care facility, a licensed residential care facility for 16persons with chronic life-threatening illness, a hospice or a licensed home 17health agency, a licensed residential care facility for the elderly, the owner 18or operator and any trained staff of a licensed clinic, facility hospice or 19home health agency, group home, halfway house, if designated as a 20caregiver by a patient; or21(B) an individual who has been designated as a caregiver by one or 22more patients.23(2) A caregiver shall be at least 18 years of age, unless the caregiver 24is the parent of a minor child who is a patient or the caregiver is a person 25otherwise entitled to make medical decisions under state law, or it can be 26proven to the agency that no other viable option for a caregiver is 27available.28(f) "Certification" means a document given by a medical provider to a 29patient that states that the patient has a condition or illness that meets the 30guidelines of this act.31(g) "Department" means the department of health and environment.32(h) "Dispensary" means an entity that has been licensed by the 33department pursuant to this act to:34(1) Purchase medical cannabis or medical cannabis products from a 35licensed medical cannabis commercial grower or medical cannabis 36manufacturer;37(2) sell medical cannabis or medical cannabis products to patients and 38caregivers as defined under this act; or 39(3) sell or transfer products to another dispensary.40(i) "Extract" is defined as the final product, derived by various 41methods, of separating plant material from chemical compounds.42(j) "Entity" means an individual, general partnership, limited 43partnership, limited liability company, trust, estate, association, 1corporation, cooperative or any other legal or commercial entity.2(k) "Identification card" means a document issued by the department 3that identifies a person as a registered qualifying patient, registered 4designated primary caregiver or employee of a registered dispensary.5(l) "Kansas resident" means an individual who can provide proof of 6residency as required by this act.7(m) "Laboratory" means a public or private laboratory licensed 8pursuant to this act to conduct testing and research on medical cannabis 9and medical cannabis products.10(n) "Licensee" means any person or entity holding a license to 11operate a dispensary, testing laboratory, cultivation facility or 12manufacturing laboratory.13(o) "Licensed premises" means the premises specified in an 14application for a medical cannabis business license pursuant to this act that 15is owned or in possession of the licensee and within which the licensee is 16authorized to cultivate, manufacture, distribute, sell, store, transport, test or 17research medical cannabis or medical cannabis products in accordance 18with the provisions of this act.19(p) "Manufacture" means the production, propagation, compounding 20or processing of a medical cannabis product, excluding cannabis plants, 21either directly or indirectly by extraction from substances of natural or 22synthetic origin or independently by means of chemical synthesis or by a 23combination of extraction and chemical synthesis.24(q) "Material change" means any change that would require a 25substantive revision to the standard operating procedures of a licensee for 26the cultivation or production of medical cannabis or medical cannabis 27products.28(r) "Medical condition" means either a temporary disability or illness 29caused by an injury or surgery or a permanent disability or illness that:30(1) Substantially limits the ability of the person to conduct one or 31more major life activities as defined in the Americans with disabilities act 32of 1990; or33(2) if not alleviated, may cause serious harm to the patient's safety, 34physical or mental health.35(s) "Medical provider" means a physician, physician's assistant or an 36advanced practice registered nurse who possesses a license in good 37standing to practice medicine or osteopathy issued by the Kansas board of 38healing arts or board of nursing and who has taken responsibility for an 39aspect of the medical care, treatment, diagnosis, counseling or referral of a 40patient and who has conducted a medical examination of that patient 41before recording in the patient's medical record the physician's or 42advanced practice registered nurse's assessment of whether the patient has 43an illness or medical condition that meets the guidelines of this act.1(t) (1) "Medical cannabis product" or "product" means a product that 2contains cannabinoids that have been extracted from plant material or the 3resin therefrom by physical or chemical means and is intended for 4administration to a qualified patient including, but not limited to, oils, 5tinctures, edibles, pills, topical forms, gels, creams, vapors, patches, 6liquids and forms administered by a nebulizer.7(2) "Medical cannabis product" or "product" does not include 8cannabis in the form of a live plant.9(u) "Medical use" means the acquisition, possession, use, delivery, 10transfer or transportation of medical cannabis, medical cannabis products, 11medical cannabis devices or paraphernalia relating to the administration of 12medical cannabis to treat a licensed patient.13(v) "Owner" means a direct beneficial owner including, but not 14limited to, all persons or entities as follows:15(1) All shareholders owning an interest of a corporate entity and all 16officers of a corporate entity;17(2) all partners of a general partnership;18(3) all general partners and all limited partners that own an interest in 19a limited partnership;20(4) all members that own an interest in a limited liability company;21(5) all beneficiaries that hold a beneficial interest in a trust and all 22trustees of a trust;23(6) all persons or entities that own interest in a joint venture;24(7) all persons or entities that own an interest in an association;25(8) the owners of any other type of legal entity; and26(9) any other person holding an interest or convertible note in any 27entity that owns, operates or manages a licensed facility.28(w) "Patient" means a person who has been diagnosed by a medical 29provider as having a debilitating medical condition and as such is qualified 30for coverage under the Kansas health freedom act, whether a temporary 31disability or illness, due to injury or surgery or a permanent disability or 32illness that substantially limits the ability of the person to conduct one or 33more major life activities, as defined in the Americans with disabilities act 34of 1990 or, if not alleviated, may cause serious harm to the patient's safety 35or physical or mental health.36(x) "Package" or "packaging" means any container or wrapper that 37may be used by a medical cannabis business to enclose or contain medical 38cannabis.39(y) (1) "Person" means a natural person, partnership, association, 40business trust, company, corporation, estate, limited liability company, 41trust or any other legal entity or organization or a manager, agent, owner, 42director, servant, officer or employee thereof.43(2) "Person" does not include any governmental organization.1(z) "Private business information" means information that, if 2disclosed, would give advantage to competitors or bidders including, but 3not limited to, information related to the planning, site location, 4operations, strategy or product development and marketing of an applicant, 5unless approval for release of those records is granted by the business.6(aa) (1) "Research laboratory" means a person or entity approved 7pursuant to this act to conduct medical cannabis research.8(2) "Research laboratory" does not include a medical cannabis 9business.10(bb) "Revocation" means the final decision by the department that 11any license issued pursuant to this act is rescinded because the individual 12or entity does not comply with the applicable requirements set forth in this 13act.14(cc) (1) "School" means a public or private preschool or a public or 15private elementary or secondary school that is used for school classes and 16instruction.17(2) "School" does not include a home school, daycare or child care 18facility.19(dd) "Seed-to-sale tracking system" means a system that is used to 20track the production, transportation, destruction and sales of legal medical 21cannabis and medical cannabis products in a system, allowing regulatory 22agencies to view reports in real time.23(ee) "Seedling" means a nonflowering plant grown from a seed or cut 24or that was cloned from a mother plant and has shown no signs of 25flowering.26(ff) "Testing laboratory" or "laboratory" means a public or private 27laboratory licensed pursuant to this act, to conduct testing and research on 28medical cannabis and medical cannabis products.29(gg) "Universal symbol" means the image established by the 30department or Kansas medical cannabis compliance agency and made 31available to licensees through the department's or agency's website 32indicating that the medical cannabis or the medical cannabis product 33contains tetrahydrocannabinol.34New Sec. 3. (a) The purpose of this section is to set forth general 35standards and requirements for the issuance of patient and caregiver 36identification cards. It is the intent of the legislature for this section to 37provide unimpeded and legal access to patients and to prevent the 38diversion of medical cannabis to the illicit market.39(b) The agency shall develop such forms, certificates, licenses, 40identification cards and applications as necessary for the administration of 41this section, including, but not limited to:42(1) An application fee and a renewal fee in an amount of not to 43exceed $25. Such fees shall be waived for patients on disability or state 1insurance. The agency shall not issue an identification card to a patient 2who is younger than 18 years of age unless such issuance is recommended 3by two medical providers; and4(2) requiring the custodial parent or legal guardian with responsibility 5for health care decisions for the minor patient to be the minor patient's 6licensed caregiver.7(c) An identification card or the equivalent thereof that is issued 8under the laws of another state, district, territory, commonwealth or insular 9possession of the United States that allows, verifiable by the jurisdiction of 10issuance, a visiting patient to possess medical cannabis for medical 11purposes, shall have the same force and effect as an identification card 12issued by the agency.13(d) Applicants may appeal rejections to the agency for review. The 14agency's rejection of an application or renewal shall be considered a final 15department action, subject to judicial review. All administrative 16proceedings shall be subject to the Kansas administrative procedure act.17(e) Failure to comply with any rules and regulations adopted pursuant 18to this act may result in administrative penalties and revocation of license.19(f) The agency shall not have the authority to apply or enforce any 20rule or regulation that would impose an undue burden on any one or more 21licensees or certificate holders, any qualifying patients or act to undermine 22the purposes of this section.23New Sec. 4. (a) The purpose of this section is to set forth general 24standards and requirements and prohibit any medical provider from being 25punished or denied any right or privilege for having recommended medical 26cannabis to a patient for medical therapeutic use. The legislature intends 27the guidelines in this section to help maintain the integrity of Kansas 28medical providers recommending medical cannabis.29(b) The agency shall adopt rules and regulations to establish 30standards for licensed medical providers, including, but not limited to:31(1) Certifying that medical providers do not have an ownership level 32with a licensed medical cannabis dispensary; and33(2) requiring medical providers to certify that a patient has an illness 34or medical condition.35(c) A medical provider shall not be subject to arrest, prosecution or 36penalty in any manner or denied any right or privilege, including, but not 37limited to, civil penalty or disciplinary action by the state board of healing 38arts or by any other occupational or professional licensing board or bureau, 39solely for providing written certifications or otherwise stating that, in the 40medical provider's professional opinion, a patient is likely to receive 41therapeutic benefit from the medical use of medical cannabis to treat or 42alleviate the patient's medical condition or conditions or symptoms 43associated with the medical condition.1(d) Nothing in the Kansas health freedom act shall prevent a 2professional licensing board from sanctioning a medical provider for 3failing to properly evaluate a patient's medical condition or otherwise 4violating the standard of care for evaluating medical conditions.5New Sec. 5. (a) There is hereby established within the department of 6health and environment the Kansas medical cannabis agency. The 7department shall provide support staff to perform designated duties of the 8agency.9(b) The department shall also provide office space for meetings of the 10agency.11(c) The agency shall hold quarterly public meetings to gather public 12feedback. The agency shall adopt rules and regulations and guidelines 13relating to how such quarterly public meetings shall be conducted.14(d) The agency shall: 15(1) Establish all guidelines regarding: 16(A) Licensing, applications, security, testing, transportation, research;17(B) the receipt, storage, packaging, labeling, handling, 18manufacturing, tracking and dispensing of products containing medical 19cannabis;20(C) public health policy and public safety policy;21(D) agronomic, horticultural, sustainable energy and water usage best 22practices; and23(E) medical and pharmacopoeia best practices;24(2) contract with third-party vendors and other governmental entities 25in order to carry out the respective duties and functions as specified in this 26act;27(3) upon complaint or upon the agency's own motion and upon a 28completed investigation, levy fines as prescribed in this act and suspend or 29revoke licenses pursuant to this act;30(4) issue subpoenas for the appearance or production of persons, 31records and things in connection with disciplinary or contested cases 32considered by the department;33(5) apply for injunctive or declaratory relief to enforce the provisions 34of this act and any rules and regulations adopted pursuant to this section;35(6) inspect and examine, with notice provided in accordance with this 36act, all licensed premises;37(7) work with the Kansas state banking commissioner, department of 38commerce and the state treasurer to develop good practices and standards 39for banking and finance for medical cannabis businesses;40(8) establish internal control procedures for licenses including 41accounting procedures, reporting procedures and personnel policies;42(9) establish a fee schedule and collect fees for performing criminal 43history record checks required under this act in an amount of not to exceed 1the actual cost incurred for each background check;2(10) require verification for sources of finance for licensees; and3(11) establish procedures and guidelines for:4(A) Adverse event reporting and tracking;5(B) product recall reporting and tracking; and6(C) complaints reporting and tracking.7(e) The agency, in conjunction with the department, shall employ an 8executive director and other personnel as necessary to assist the 9compliance agency in carrying out its duties.10(f) The agency shall not employ an individual if any of the following 11circumstances exist:12(1) The individual has a direct or indirect interest in a licensed 13medical cannabis business; or14(2) the individual or the individual's spouse, parent, child, spouse of a 15child, sibling or spouse of a sibling has an application for a medical 16cannabis business license pending before the department or is a member of 17the board of directors of a medical cannabis business or is an individual 18financially interested in any licensee or medical cannabis business.19(g) All officers and employees of the agency shall be in the exempt 20unclassified service as provided for in K.S.A. 75-2935, and amendments 21thereto.22(h) The director may delegate to any officer or employee of the 23department any of the powers of the executive director and may designate 24any officer or employee of the department to perform any of the duties of 25the executive director.26(i) The department shall create employment positions necessary for 27the implementation of its obligations pursuant to this act, including, but 28not limited to, agency investigators and a senior agency director. The 29department and the agency, the senior director, the executive director and 30Kansas department of health and environment investigators shall have all 31the powers of any peace officer to:32(1) Investigate violations or suspected violations of this act and any 33rules promulgated pursuant thereto;34(2) serve all warrants, summonses, subpoenas, administrative 35citations, notices or other processes relating to the enforcement of laws 36regulating medical cannabis and medical cannabis product;37(3) assist or aid any law enforcement officer in the performance of 38such law enforcement officer's duties upon such law enforcement officer's 39request or the request of other local officials having jurisdiction;40(4) require any licensee, upon 24 hours' notice to permit an inspection 41of licensed premises during business hours or at any time of apparent 42operation, cannabis equipment and cannabis accessories or books and 43records and to permit the testing of or examination of medical cannabis or 1medical cannabis product; and2(5) require applicants to submit complete and current applications, 3information required by this act and fees and approve material changes 4made by the applicant or licensee.5(j) The department shall address issues related to the medical 6cannabis program in Kansas including, but not limited to, monitoring and 7disciplinary actions as they relate to the medical cannabis program.8(1) The department or the department's designee may perform on-site 9assessments of a licensee or applicant for any medical cannabis business 10license issued pursuant to this act to determine compliance with this act or 11submissions made pursuant to this section. The department may enter the 12licensed premises of a medical cannabis business licensee or applicant to 13assess or monitor compliance.14(2) Inspections shall be limited to twice per calendar year and 24 15hours' of notice shall be provided to a medical cannabis business applicant 16or licensee prior to an on-site assessment. Additional inspections may 17occur when the department shows that an additional inspection is 18necessary due to a violation of this act. Such inspection may be without 19notice if the department believes that such notice will result in the 20destruction of evidence.21(3) The department may review relevant records of a licensee and 22may require and conduct interviews with such persons or entities affiliated 23with such entities, for the purpose of determining compliance with 24department requirements and applicable laws. However, prior to 25conducting any interviews with the licensee, such licensee shall be 26afforded sufficient time to secure legal representation during such 27questioning if requested by such licensee or any of its agents or employees 28or contractors.29(4) The department shall refer complaints alleging criminal activity 30that are made against a licensee to appropriate Kansas state or local law 31enforcement authorities.32(A) Disciplinary action may be taken against an applicant or licensee 33under this act for not adhering to the law pursuant to the terms, conditions 34and guidelines set forth in this act.35(B) Disciplinary actions may include revocation, suspension or denial 36of an application, license or final authorization and other action deemed 37appropriate by the department.38(C) Disciplinary actions may be imposed upon a licensee for:39(i) Failure to comply with or satisfy any provision of this section;40(ii) falsification or misrepresentation of any material or information 41submitted to the department;42(iii) failing to allow or impeding a monitoring visit by authorized 43representatives of the department;1(iv) failure to adhere to any acknowledgement, verification or other 2representation made to the department;3(v) failure to submit or disclose information required by this section 4or otherwise requested by the department;5(vi) failure to correct any violation of this section cited as a result of a 6review or audit of financial records or other materials;7(vii) failure to comply with requested access by the department to the 8licensed premises or materials;9(viii) failure to pay a required monetary penalty;10(ix) diversion of medical cannabis or any medical cannabis product, 11as determined by the department; or12(x) threatening or harming a patient, a medical practitioner or an 13employee of the department.14(k) Disciplinary actions against a licensee may include the imposition 15of monetary penalties, which may be assessed by the department.16(l) (1) Penalties for sales by dispensary to persons other than those 17allowed by law occurring within any two year time period may include an 18initial fine of $1,000.00 for a first violation and a fine of $5,000.00 for any 19subsequent violation. The dispensary may be subject to a revocation of any 20license granted pursuant to this act upon a showing that the violation was 21willful or grossly negligent.22(2) First offense for intentional and impermissible diversion of 23medical cannabis or medical cannabis products by a patient or caregiver to 24an unauthorized person shall not be punished under a criminal statute but 25may be subject to a fine of $2,000.00.26(3) The second offense for intentional and impermissible diversion of 27medical cannabis or medical cannabis products by a patient or caregiver to 28an unauthorized person shall not be punished under a criminal statute but 29may be subject to a fine of not to exceed $5,000.00 and may result in 30revocation of the license upon a showing that the violation was willful or 31grossly negligent.32(m) A licensee whose license has been summarily suspended or who 33has received a notice of contemplated action to suspend or revoke a license 34or take other disciplinary action may request a hearing in accordance with 35the Kansas administrative procedure act.36(n) It shall be a class B misdemeanor for any person, including an 37employee or official of the agency or another state agency or local 38government, to breach the confidentiality of information obtained pursuant 39to this act.40(o) (1) The agency shall maintain pages on the department website:41(A) To house information for the public on the act; and42(B) to facilitate implementation of the act.43(2) Information to be included, either by text or link, may include, but 1shall not be limited to:2(A) Medical provider search;3(B) caregiver search;4(C) dispensary search;5(D) customer service phone number and email;6(E) information and contacts for the appeals process;7(F) electronic application forms; and8(G) electronic crop damage report form including a portal to upload 9documents and pictures.10(p) All electronic forms for licensees and any other forms as required 11by the agency.12(q) The agency shall adopt rules and regulations concerning the 13storage of, warehouses for and transportation of medical cannabis and 14medical cannabis products.15(r) The agency shall develop a universal symbol indicating the 16package contains medical cannabis.17(s) The agency shall establish a seed to sale tracking system to be 18utilized by licensees.19(t) The inventory tracking system licensees use shall allow for 20integration of other seed-to-sale systems and, at a minimum, shall include 21the following:22(1) Notification of when medical cannabis seeds are planted;23(2) notification of when medical cannabis plants are harvested and or 24destroyed;25(3) notification of when medical cannabis is transported, sold, stolen, 26diverted or lost;27(4) a complete inventory of all medical cannabis, seeds, plant tissue, 28seedlings, plants, usable medical cannabis or trim, leaves and other plant 29matter, batches of extract and medical cannabis concentrates and medical 30cannabis products; and31(5) all samples sent to a testing laboratory, an unused portion of a 32sample returned to a licensee, all samples utilized by licensee for purposes 33of negotiating a sale and all samples used for quality testing by a licensee.34(u) Each licensee shall use a seed-to-sale tracking system enacted by 35the Kansas medical cannabis agency.36(v) The agency shall require that each licensee keep records for every 37transaction with another licensee, patient or caregiver. Inventory shall be 38tracked and updated after each individual sale and reported to the agency. 39These records shall include, but not be limited to, the following:40(1) The name and license number of the medical cannabis business 41that cultivated, manufactured or sold the medical cannabis or medical 42cannabis product;43(2) the address and phone number of the medical cannabis business 1that cultivated, manufactured or sold the medical cannabis or medical 2cannabis product;3(3) the type of product received during the transaction;4(4) the batch number of the medical cannabis plant used;5(5) the date of the transaction;6(6) the total spent in dollars;7(7) all point-of-sale records;8(8) tax records; and9(9) any additional information as may be required by the agency.10(w) All inventory tracking records containing patient information 11shall comply with all relevant state and federal laws including this act and 12shall not be retained by any business for more than sixty days.13(x) The agency shall establish a medical cannabis patient and 14caregiver registry.15(1) The medical cannabis patient and caregiver registry shall be 16accessible to Kansas-licensed medical cannabis dispensaries to verify the 17license of a patient or caregiver by the 20-digit alphanumeric 18identification.19(2) All records regarding a medical cannabis patient and caregiver 20licensee shall be maintained by the compliance agency and shall be 21deemed confidential. Such records shall be marked as confidential, shall 22not be made available to the public and shall only be made available to the 23licensee, designee of the licensee, any medical provider of the licensee or 24the caregiver of the licensee. No personally identifiable information, as 25defined under HIPAA, shall be stored at the department.26(3) A log shall be kept with the file of the patient and caregiver 27licensee to record any event in which the records of the licensee were 28made available and to whom the records were provided.29(4) The department shall ensure that all application records and 30information are sealed to protect the privacy of medical cannabis patient 31and caregiver license applicants.32(5) (A) (i) An application or renewal and supporting information 33submitted by a patient and caregiver under the provisions of this act 34including, without limitation, information regarding the medical provider 35of the qualifying patient shall be considered confidential medical records 36that are exempt from the Kansas open records act.37(ii) The dispensary records with patient and caregiver information 38shall be treated as confidential records that are exempt from the Kansas 39open records act.40(iii) All financial information provided by an applicant in the 41applicant's application to the agency shall be treated as confidential 42records that are exempt from the Kansas open records act.43(iv) All information provided by an applicant that constitutes private 1business information shall be treated as confidential records that are 2exempt from the Kansas open records act.3(B) The provisions of this subsection shall expire on July 1, 2031, 4unless the legislature reviews and acts to continue such provisions 5pursuant to K.S.A. 45-229, and amendments thereto, prior to July 1, 2031.6(6) Kansas medical cannabis agency staffers shall not be excluded 7from employment due to any offense consisting of conduct for which this 8act would have prevented a conviction, but the conduct either occurred 9prior to the enactment of this act or was prosecuted by an authority other 10than the state of Kansas, whether as a patient or caregiver.11New Sec. 6. The agency shall adopt rules and regulations for all 12aspects of the licensing, application, security, testing, transportation, 13research and procedures related to the receipt, storage, packaging, labeling, 14handling, manufacturing, tracking and dispensing of products containing 15medical cannabis. The agency shall not license any facility that is not 16owned by two-thirds Kansas residents. Nothing in this act shall prevent 17municipalities from enacting zoning regulations to limit the location of 18medical cannabis facilities.19New Sec. 7. (a) Notwithstanding any other law to the contrary, it shall 20be unlawful to subject a person to the seizure and forfeiture of such 21person's property on the basis that a patient uses medical cannabis as a 22medical treatment or such person is a family member living with such 23patient, is the patient's caregiver, is the patient's medical provider, is the 24individual who provided medical cannabis to the patient or otherwise 25lawfully participated in the medical cannabis program 26(b) The presence of cannabinoid metabolites in a person's bodily 27fluids, nor conduct related to the use of medical cannabis by a custodial or 28noncustodial parent, grandparent or legal guardian shall not form the sole 29or primary basis for any action or proceeding by a child welfare agency, 30family or juvenile court.31(c) Patients protected under this act shall not be disqualified from any 32medical care, including organ transplants. A patient's medical care 33pursuant to this act shall not be restricted and shall be available in any 34environment where other medications are allowed.35(d) A patient's medical use of medical cannabis shall not constitute 36the use of an illicit substance and shall not constitute a violation of a 37patient's probation or parole.38(e) This act shall in no way impede the rights of indigenous peoples.39(f) A patient or caregiver shall not be denied the right to own, 40purchase or possess a firearm, ammunition or firearm accessories based 41solely on his or her status as a patient or caregiver. No state or local 42agency, municipal or county governing authority shall restrict, revoke, 43suspend or otherwise infringe upon the right of a person to own, purchase 1or possess a firearm, ammunition or firearm accessories or any related 2firearms license or certification based solely on such person's status as a 3patient or caregiver4(g) Medical cannabis patients shall be protected from warrantless 5medical record searches. This protection shall extend to entities working in 6ancillary capacities, such as training and education, professional 7development, public relations, packaging and related fields.8(h) When a state or locally law enforcement agency encounters a 9patient in the course of an investigation, such law enforcement agency 10shall not provide any identifying information to any federal or out-of-state 11law enforcement authority that does not recognize the protection of the 12Kansas health freedom act.13(i) Card holding, non-resident, patients from other states shall be 14allowed, pursuant to this act, to purchase, possess and use medical 15cannabis while in the state of Kansas.16(j) If the department fails to adopt temporary or permanent rules and 17regulations on or before December 31, 2026, a patient, patient caregiver or 18entity may commence an action in a court of competent jurisdiction to 19compel the department to perform the actions mandated pursuant to the 20provisions of this act.21(k) If the agency fails to issue a valid identification card in response 22to a valid application or renewal submitted pursuant to this act within 30 23business days of submission, a copy of the patient's application or renewal 24application, coupled with the receipt, shall be deemed a valid identification 25card.26(l) If at any time after the 180 business days following the effective 27date of the Kansas health freedom act, the department is not accepting 28patient applications, including if it has not created rules and regulations 29allowing patients to submit applications, a certification letter from their 30medical provider shall be deemed a valid identification card.31(m) A medical cannabis patient or caregiver shall not be denied 32eligibility in public assistance programs including, but not limited to, 33medicaid, the supplemental nutrition assistance program, the women, 34infants and children nutrition program, temporary assistance for needy 35families or other such public assistance programs based solely on his or 36her status as a medical cannabis patient or caregiver, unless required by 37federal law.38(n) A government medical assistance program shall not be required to 39reimburse a person for costs associated with the medical use of cannabis 40unless federal law requires reimbursement.41(o) (1) Impaired drivers shall not be protected by this act while 42operating, navigating or being in actual physical control of any motor 43vehicle, school bus, public transport, aircraft or motorboat. However, the 1presence of metabolites shall not automatically denote impairment.2(2) Educational outreach materials to prevent driving while impaired 3shall be posted on the agency website and made available to dispensaries, 4including printable information, instructional videos and educational 5materials.6(p) No registered patient may smoke medical cannabis on the grounds 7of any school.8(1) Juvenile registered patients receiving medication from the school 9nurse, a parent or a caregiver may receive medication on school grounds.10(2) Post secondary patients shall not be impeded from medicating 11either individually or by the facilitation of such patient's caregiver on 12school grounds as long as the delivery method does not violate this act.13(3) Juvenile and post secondary patients shall not be impeded from 14participation in any extracurricular activities or regular school activities 15solely because such persons are patients. School personnel may administer 16cannabis that is obtained for medical use pursuant to this act by a student 17who is a qualified patient.18(q) No patient may smoke medical cannabis in any and all places 19where tobacco smoking is prohibited.20New Sec. 8. The agency shall adopt rules and regulations for all 21aspects of patient possession and acquisition. The agency may set a limit 22on the amount of marijuana that may be possessed or purchased by or on 23behalf of a single qualifying patient in a thirty-day period, provided that 24limit is not less than four ounces of dried, unprocessed cannabis or its 25equivalent. Any such limit shall not apply to a qualifying patient with 26written certification from two independent physicians that there are 27compelling reasons why the qualifying patient needs a greater amount than 28the limit established by the agency.29New Sec. 9. (a) There is hereby established in the state treasury the 30medical cannabis tax fund. All moneys credited to the medical cannabis 31tax fund shall be expended or transferred only for the purposes and in the 32manner provided by this section. All expenditures from the medical 33cannabis tax fund shall be made in accordance with appropriation acts for 34the financing of the administration of this act and the remaining 35unencumbered balance shall be allocated for medical cannabis research, 36public health, mental health, telehealth initiatives, substance abuse, K-12 37school health, substance abuse prevention and mental health programs, 38broadband or high speed internet connectivity initiatives and property tax 39relief for those 60 years of age and older.40(b) The fund shall be a continuing fund, not subject to fiscal year 41limitations and shall consist of all monies received by the department from 42fees and fines collected pursuant to this act and all monies received by the 43Kansas department of revenue from tax proceeds collected per this act. All 1monies accruing to the credit of the fund are hereby appropriated and may 2be budgeted and expended by the department for the purposes set forth in 3this act. Expenditures from the fund shall be made upon warrants issued by 4the state treasurer against claims filed as prescribed by law with the 5director of the department of administration for approval and payment.6New Sec. 10. (a) There is hereby levied a tax at the rate of 4% on the 7gross receipts from the sale of medical cannabis and medical cannabis 8products by any dispensary.9(b) The tax imposed by this section shall be paid by the patient to the 10dispensary. It shall be the duty of each licensee subject to this section to 11collect from the patient the full amount of such tax, or an amount equal as 12nearly as possible or practicable to the average equivalent thereto. Each 13dispensary collecting the tax imposed hereunder shall be responsible for 14paying over the same to the department of revenue in the manner 15prescribed by this section and the department of revenue shall administer 16and enforce the collection of such tax.17(c) The taxes levied and collected pursuant to this section shall 18become due and payable monthly, or on or before the 25th day of the month 19immediately succeeding the month in which such tax is collected, except 20that any cannabis business filing an annual or quarterly return under the 21Kansas retailers' sales tax act, as prescribed in K.S.A. 79-3607, and 22amendments thereto, shall, upon such conditions as the secretary of 23revenue may prescribe, pay the tax required by this section on the same 24basis and at the same time the dispensary pays such retailers' sales tax. 25Each dispensary shall make a true report to the department of revenue, on 26a form prescribed by the secretary of revenue, providing such information 27as may be necessary to determine the amounts to which any such tax shall 28apply for all gross receipts derived from the sale of medical cannabis and 29medical cannabis products for the applicable month or months, which 30report shall be accompanied by the tax disclosed thereby. Records of gross 31receipts derived from the sale of medical cannabis and medical cannabis 32products shall be kept separate and apart from the records of other retail 33sales made by a dispensary in order to facilitate the examination of books 34and records.35(d) The secretary of revenue or the secretary's authorized 36representative shall have the right at all reasonable times during business 37hours to make such examination and inspection of the books and records 38of a dispensary as may be necessary to determine the accuracy of such 39reports required by this section.40(e) The secretary of revenue is hereby authorized to administer and 41collect the tax imposed under this section and to adopt such rules and 42regulations as may be necessary for the efficient and effective 43administration and enforcement of the collection thereof. Whenever any 1dispensary liable to pay the tax imposed by this section refuses or neglects 2to pay the same, the amount, including any penalty, shall be collected in 3the manner prescribed for the collection of the retailers' sales tax by K.S.A. 479-3617, and amendments thereto.5(f) The secretary of revenue shall remit all revenue collected under 6the provisions of this section to the state treasurer in accordance with the 7provisions of K.S.A. 75-4215, and amendments thereto. Upon receipt of 8each such remittance, the state treasurer shall deposit such amount in the 9state treasury to the credit of the medical cannabis tax fund established 10pursuant to section 8, and amendments thereto.11(g) Whenever, in the judgment of the secretary of revenue, it is 12necessary, in order to secure the collection of any tax, penalties or interest 13due, or to become due, under the provisions of this section the secretary 14may require any person subject to such tax to file a bond with the director 15of taxation under conditions established by and in such form and amount 16as prescribed by rules and regulations adopted by the secretary.17(h) The amount of tax imposed by this section shall be assessed 18within three years after the return is filed, and no proceedings in court for 19the collection of such taxes shall be initiated after the expiration of such 20period except in the cases of fraud. In the case of a false or fraudulent 21return with intent to evade tax, the tax may be assessed or a proceeding in 22court for collection of such tax may be initiated at any time, within two 23years from the discovery of such fraud. No refund or credit shall be 24allowed by the director after three years from the date of payment of the 25tax as provided in this section unless before the expiration of such period a 26claim therefor is filed by the taxpayer. No suit or action to recover on any 27claim for refund shall be commenced until after the expiration of six 28months from the date of filing a claim therefor with the director. Before 29the expiration of time prescribed in this section for the assessment of 30additional tax or the filing of a claim for refund, the director is hereby 31authorized to enter into an agreement in writing with the taxpayer 32consenting to the extension of the periods of limitations for the assessment 33of tax or for the filing of a claim for refund, at any time prior to the 34expiration of the periods of limitations. The period so agreed upon may be 35extended by subsequent agreements in writing made before the expiration 36of the period previously agreed upon.37(i) On or before the 25th day of each calendar month, every dispensary 38subject to the provisions of this section shall make a return to the director 39of taxation upon forms prescribed and furnished by the director, stating:40(1) The name and address of the dispensary;41(2) the total amount of gross sales subject to the tax imposed by this 42section during the preceding calendar month; and43(3) any other pertinent information the director requires.1(j) At the time of making the return, the person making the return 2shall pay to the director of taxation the amount of tax levied by this section 3as applicable to the person submitting the return. The director of taxation 4may extend the time for submitting returns and paying the tax for any 5period not to exceed 60 days, under rules and regulations adopted by the 6secretary of revenue.7(k) If any taxpayer fails to pay the tax levied by this section at the 8time required by or under the provisions of this section there shall be 9added to the unpaid balance of the tax, interest at the rate per month 10prescribed by K.S.A. 79-2968(a), and amendments thereto, from the date 11the tax was due until paid.12(l) If any taxpayer due to negligence or intentional disregard fails to 13file a return or pay the tax due at the time required by or under the 14provisions of this section there shall be added to the tax a penalty in an 15amount equal to 10% of the unpaid balance of tax due.16(m) If any person fails to make a return, or to pay any tax, within six 17months from the date the return or tax was due, except in the case of an 18extension of time granted by the secretary of revenue or the secretary's 19designee, there shall be added to the tax due a penalty equal to 25% of the 20unpaid balance of such tax due.21(n) If any taxpayer fails to file a return or pay the tax that is due at the 22time required by or under the provisions of this section there shall be 23added to the tax an additional amount equal to 1% of the unpaid balance of 24the tax due for each month or fraction thereof during which such failure 25continues, not exceeding 24% in the aggregate, plus interest at the rate 26prescribed by K.S.A. 79-2968(a), and amendments thereto, from the date 27the tax was due until paid. Notwithstanding the foregoing, in the event an 28assessment is issued following a field audit for any period for which a 29return was filed by the taxpayer and all of the tax was paid pursuant to 30such return, a penalty shall be imposed for the period included in the 31assessment in an amount of 1% per month not exceeding 10% of the 32unpaid balance of tax due shown in the notice of assessment. If, after 33review of a return for any period included in the assessment, the secretary 34or secretary's designee determines that the underpayment of tax was due to 35the failure of the taxpayer to make a reasonable attempt to comply with the 36provisions of this section such penalty shall be imposed for the period 37included in the assessment in the amount of 25% of the unpaid balance of 38tax due.39(o) If any taxpayer, with fraudulent intent, fails to pay any tax or 40make, render or sign any return, or to supply any information, within the 41time required by or under the provisions of this section there shall be 42added to the tax a penalty in an amount equal to 50% of the unpaid balance 43of tax due.1(p) Penalty or interest applied under the provisions of subsections (k) 2and (n) shall be in addition to the penalty added under any other provisions 3of this section, but the provisions of subsections (l) and (m) shall be 4mutually exclusive of each other.5(q) Whenever the secretary of revenue or the secretary's designee 6determines that the failure of the taxpayer to comply with the provisions of 7subsections (l) and (m) was due to reasonable causes, the secretary or the 8secretary's designee may waive or reduce any of the penalties and may 9reduce the interest rate to the underpayment rate prescribed and 10determined for the applicable period under section 6621 of the federal 11internal revenue code as in effect on January 1, 2026, upon making a 12record of the reasons therefor.13(r) In addition to all other penalties provided by this section, any 14person who willfully fails to make a return or to pay any tax levied by this 15section who makes a false or fraudulent return, fails to keep any books or 16records necessary to determine the accuracy of the person's reports, who 17willfully violates any regulations of the secretary of revenue, for the 18enforcement and administration of this section, who aids and abets another 19in attempting to evade the payment of any tax levied by this section or 20who violates any other provision of this section, shall, upon conviction 21thereof, be fined not less than $100 nor more than $1,000, be imprisoned 22in the county jail not less than one month nor more than six months, or be 23both so fined and imprisoned, in the discretion of the court.24(s) The director of taxation or the secretary of health and environment 25may enjoin any person from engaging in business as a dispensary when the 26dispensary is in violation of any of the provisions of this section and shall 27be entitled in any proceeding brought for that purpose to have an order 28restraining the person from engaging in business as a cannabis business. 29No bond shall be required for any such restraining order or for any 30temporary or permanent injunction issued in that proceeding.31(t) If a dispensary violates any of the provisions of this section, the 32secretary of health and environment may suspend or revoke the license of 33such dispensary or may impose a civil fine on such dispensary.34(u) The provisions of K.S.A. 75-5133, 79-3605, 79-3609, 79-3610, 3579-3611, 79-3612, 79-3613, 79-3615, 79-3617 and 79-3619, and 36amendments thereto, relating to enforcement, collection and 37administration, insofar as practicable, shall have full force and effect with 38respect to taxes levied by this section. As used in such statutes and applied 39to this section, "director" means the director of taxation. The provisions of 40K.S.A. 74-2422, 74-2425, 74-2426 and 74-2427, and amendments thereto, 41relating to the approval of rules and regulations, and the adoption of 42uniform rules and regulations for such hearings and for appeals from 43orders of the director of taxation and prescribing the duties of county 1attorneys with respect to such appeals, insofar as practicable, shall have 2full force and effect with respect to taxes levied by, and proceedings under, 3the provisions of this section.4(v) Whenever the secretary issues a dispensary license, the secretary 5shall promptly notify the director of taxation of such issuance. The notice 6shall include the name of the licensee and the address of the licensed 7premises. Whenever the secretary revokes or suspends any such license or 8whenever any such license expires, the secretary shall likewise notify the 9director of taxation.10(w) The director of taxation shall administer the provisions of this 11section and the secretary of revenue shall adopt rules and regulations 12necessary to carry out the provisions and intent of this section. The 13director of taxation shall appoint such agents and employees as the 14secretary may deem necessary for the proper enforcement and 15administration of such sections. When, in the judgment of the director of 16taxation, it is necessary in order to secure the collection of any such tax, 17penalties or interest due thereon, or to become due under such sections, the 18director may require any person subject to such tax to file a bond with the 19director in such form and amount as the director may prescribe.20New Sec. 11. (a) The agency, with the aid of the Kansas department 21of administration, shall develop a website for license applications.22(b) All applicants for a dispensary license, laboratory license or other 23license that is authorized by this act shall undergo a state criminal record 24history background check pursuant to K.S.A. 2025 Supp. 22-4714, and 25amendments thereto, within thirty days prior to the application for the 26license, including:27(1) Individual applicants applying on their own behalf;28(2) individuals applying on behalf of an entity;29(3) all principal officers of an entity; and30(4) all owners of an entity.31(c) All applicable fees charged by Kansas bureau of investigation are 32the responsibility of the applicant and shall not be higher than fees charged 33to any other person or industry for such background checks.34(d) In order to be considered a Kansas resident for purposes of a 35medical cannabis business application, all applicants shall provide proof of 36Kansas residency for at least two years.37(e) Approved applicants shall be issued a medical cannabis business 38license for the specific category applied under which shall act as proof of 39their approved status.40New Sec. 12. (a) A person arrested for, charged with or convicted of a 41criminal offense pursuant to Kansas statute or district or municipal code 42that was decriminalized or legalized after the date of the arrest, charge or 43conviction may file a motion of expungement to seal the record of the 1arrest, charge, conviction, supervision and related proceedings at any time 2with no fee.3(b) The convicting court shall grant a motion of expungement and 4seal the cannabis-related charge and not any other non-cannabis or non-5cannabis use related state, municipal or federal charges or convictions 6against the person.7(c) In a motion filed under subparagraph (a), the burden shall be on 8the prosecutor to establish by a preponderance of the evidence that the 9record is not eligible for sealing pursuant to this section because the 10conduct was not decriminalized or legalized.11(d) In cases that do not meet the requirements of this section, the 12court of charge may grant a motion to seal if it is in the interest of justice 13to do so. In making this determination, the court shall weigh:14(1) The interests of the petitioner in sealing the publicly available 15records of such petitioner's arrest, charge, conviction, supervision and 16related proceedings;17(2) the community's interest in retaining access to those records;18(3) the community's interest in furthering the petitioner's 19rehabilitation and enhancing the petitioner's employability; and20(4) any other information such court considers relevant.21(e) If the court grants a motion to seal under this section:22(1) The court shall order the prosecutor, any law enforcement agency 23and any pretrial, corrections or community supervision agency to remove 24from publicly available records all references that identify the petitioner as 25having been arrested, prosecuted or convicted.26(2) The prosecutor's office, any law enforcement agency and any 27pretrial, corrections or community supervision agency shall be entitled to 28retain records related to the petitioner's arrest, prosecution, conviction or 29related court proceedings in a nonpublic file.30(3) The prosecutor, any law enforcement agency and any pretrial, 31corrections or community supervision agency shall file a certification with 32the court within 90 days after the court issues an order under this section 33that, to the best of such court's knowledge and belief, all references that 34identify the petitioner as having been arrested, prosecuted or convicted 35have been removed from such court's publicly available records.36(4) The court shall order the clerk to remove or eliminate all publicly 37available court records that identify the petitioner as having been arrested, 38prosecuted or convicted.39(5) The clerk shall be entitled to retain any records related to the 40petitioner's arrest, prosecution, conviction or related court proceedings in a 41nonpublic file.42(f) In a case involving codefendants in which the court orders the 43petitioner's records sealed, the court may order that only those records or 1portions thereof related solely to the petitioner be redacted.2(g) The court need not order the redaction of references to the 3petitioner that appear in a transcript of court proceedings involving 4codefendants.5(h) The court shall not order the redaction of the petitioner's name 6from any published opinion of the trial or appellate courts that refer to the 7petitioner.8(i) Unless otherwise ordered by the court, the clerk and any other 9agency shall reply in response to inquiries from the public concerning the 10existence of records that have been sealed pursuant to this section that no 11records are available.12(j) No person as to whom relief pursuant to this section has been 13granted shall be held thereafter under any provision of law to be guilty of 14perjury or otherwise giving a false statement by reason of failure to recite 15or acknowledge such person's own arrest, charge, trial or conviction in 16response to any inquiry made of such person for any purpose.17(k) A person imprisoned solely as a result of one or more convictions 18for offenses that are expunged under this act shall be released from 19incarceration upon the issuance of an order under this subsection.20(1) The department of corrections shall allow a person to use the 21established access and review process for verifying such person's own 22records related to eligibility.23(2) No conviction vacated pursuant to this section shall serve as the 24basis for damages for time unjustly served.25(l) A person's right to expunge an expungeable offense shall not be 26limited under this section. The effect of an order of expungement shall be 27to restore the person to the status such person occupied before the arrest, 28charge or conviction.29(m) The department of corrections shall post general information on 30its website about the expungement process described in this section.31(n) If a person is arrested and the person's case is still pending but a 32sentence has not been imposed, the person may petition the court in which 33the charges are pending for an order to summarily dismiss those charges 34against him or her and expunge all official records of his or her arrest, 35plea, trial, conviction, incarceration, supervision or expungement.36(o) In the public interest, the state's attorney of a county has standing 37to file motions to vacate and expunge in the court with jurisdiction over 38the underlying conviction pursuant to this section.39(p) Any individual may file a motion to vacate and expunge a 40conviction.41(q) (1) Upon the effective date of this act, the department of 42corrections shall review all criminal history record information and 43identify all records showing persons with one or more convictions for 1offenses covered under this act and not associated with a conviction for 2any crime prohibited for expungement under K.S.A. 21-6614(e) and (f), 3and amendments thereto.4(2) Within 180 days after the effective date of this act, the department 5of corrections shall notify the prisoner review board of all such records 6that meet the criteria established in this subsection.7(3) The prisoner review board shall notify the convicting court of 8each record identified by the department of corrections. The convicting 9court may provide a written objection to the prisoner review board on the 10sole basis that the record identified does not meet the criteria in this 11section. Such an objection must be filed within 60 days or by a later date 12set by the prisoner review board after the convicting court received notice 13from the prisoner review board.14(A) In response to a written objection from a convicting court, the 15prisoner review board is authorized to conduct a hearing to evaluate the 16information provided in the objection.17(B) The prisoner review board shall make a confidential and 18privileged recommendation to the governor as to whether to grant a pardon 19authorizing expungement for each of the records identified by the 20department of corrections.21(r) The following records may be sealed:22(1) All arrests resulting in a release and without a charge;23(2) arrests or charges not initiated by arrest resulting in acquittal, 24dismissal or conviction when the conviction was reversed or vacated;25(3) arrests or charges not initiated by arrest resulting in orders of 26supervision, including orders of supervision for municipal ordinance 27violations, successfully completed by the petitioner;28(4) arrests or charges not initiated by arrest resulting in convictions, 29including convictions on municipal ordinance violations;30(5) arrests or charges not initiated by arrest resulting in orders of first 31offender probation; and32(6) arrests or charges not initiated by arrest resulting in felony 33convictions, unless otherwise excluded by this section.34(s) Records identified as eligible under this section may be sealed at 35any time.36(t) Upon becoming eligible to petition for the expungement or sealing 37of records under this section, the petitioner shall file a petition requesting 38the expungement or sealing of records with the clerk of the court where the 39arrests occurred or the charges were brought, or both. If arrests occurred or 40charges were brought in multiple jurisdictions, a petition must be filed in 41each such jurisdiction.42(u) The petition shall be verified and shall contain the petitioner's 43name, date of birth, current address and, for each arrest or charge not 1initiated by arrest sought to be sealed or expunged, the case number, the 2date of arrest, if any, the identity of the arresting authority and such other 3information as the court may require. During the pendency of the 4proceeding, the petitioner shall promptly notify the convicting court of any 5change of such petitioner's address. If the petitioner has received a 6certificate of eligibility for sealing from the prisoner review board, the 7certificate shall be attached to the petition.8(v) The convicting court shall promptly serve a copy of the petition 9and documentation to support the petition on the state's attorney or 10prosecutor charged with the duty of prosecuting the offense.11(w) Any party entitled to notice of the petition may file an objection 12to the petition. All objections shall be in writing, filed with the convicting 13court and shall state with specificity the basis of the objection. Whenever a 14person who has been convicted of an offense is granted a pardon by the 15governor that specifically authorizes expungement, an objection to the 16petition may not be filed.17(1) Objections to a petition to expunge or seal must be filed within 60 18days of the date of service of the petition.19(2) Notwithstanding any other provision of law, the court shall not 20deny a petition for sealing under this section because the petitioner has not 21satisfied an outstanding legal financial obligation established, imposed or 22originated by a court, law enforcement agency or a municipal, state, 23county or other unit of local government, including, but not limited to, any 24cost, assessment, fine or fee. An outstanding legal financial obligation does 25not include any court ordered restitution to a victim unless the restitution 26has been converted to a civil judgment. Nothing in this section waives, 27rescinds or abrogates a legal financial obligation or otherwise eliminates or 28affects the right of the holder of any financial obligation to pursue 29collection under applicable federal, state or local law.30(x) If an objection is filed, the court shall set a date for a hearing and 31notify the petitioner and all parties entitled to notice of the petition of the 32hearing date at least 30 days prior to the hearing. At the hearing, the court 33shall hear evidence on whether the petition should or should not be granted 34and shall grant or deny the petition to expunge or seal the records based on 35the evidence presented at the hearing. The court may consider the 36following:37(1) The strength of the evidence supporting the defendant's 38conviction;39(2) the reasons for retention of the conviction records by the state;40(3) the petitioner's age, criminal record history and employment 41history;42(4) the period of time between the petitioner's arrest on the charge 43resulting in the conviction and the filing of the petition under this section; 1and2(5) the specific adverse consequences the petitioner may be subject to 3if the petition is denied.4(y) After entering an order to expunge or seal records, the court shall 5provide copies of the order to the petitioner, the state's attorney or 6prosecutor charged with the duty of prosecuting the offense, the arresting 7agency, the chief legal officer of the unit of local government effecting the 8arrest and such other criminal justice agencies as may be ordered by the 9court.10(1) No court order issued under the expungement or sealing 11provisions of this section shall become final for purposes of appeal until 1230 days after service of the order on the petitioner and all parties entitled 13to notice of the petition.14(2) Unless a court has entered a stay of an order granting a petition to 15seal, all parties entitled to notice of the petition must fully comply with the 16terms of the order within 60 days of service of the order, even if a party is 17seeking relief from the order through a motion filed or is appealing the 18order.19(3) While a party is seeking relief from the order granting the petition 20to expunge through a motion filed under this section or is appealing the 21order and, unless a court has entered a stay of that order, the parties 22entitled to notice of the petition must seal but need not expunge the records 23until there is a final order on the motion for relief or, in the case of an 24appeal, the issuance of that court's mandate.25(z) If a person who has been convicted of an offense is granted a 26pardon by the governor that specifically authorizes expungement, such 27person may, upon verified petition to the court where the person was 28convicted, have a court order entered expunging the record of arrest from 29the official records of the arresting authority and order that the records of 30the court clerk be sealed until further order of the court upon good cause 31shown or as otherwise provided in subsection (y) and that the name of the 32defendant be removed from the official index.33Sec. 13. K.S.A. 2025 Supp. 21-5701 is hereby amended to read as 34follows: 21-5701. As used in K.S.A. 21-5701 through 21-5717, and 35amendments thereto:36(a) "Controlled substance" means any drug, substance or immediate 37precursor included in any of the schedules designated in K.S.A. 65-4105, 3865-4107, 65-4109, 65-4111 and 65-4113, and amendments thereto.39(b) (1) "Controlled substance analog" means a substance that is 40intended for human consumption, and at least one of the following:41(A) The chemical structure of the substance is substantially similar to 42the chemical structure of a controlled substance listed in or added to the 43schedules designated in K.S.A. 65-4105 or 65-4107, and amendments 1thereto;2(B) the substance has a stimulant, depressant or hallucinogenic effect 3on the central nervous system substantially similar to the stimulant, 4depressant or hallucinogenic effect on the central nervous system of a 5controlled substance included in the schedules designated in K.S.A. 65-64105 or 65-4107, and amendments thereto; or7(C) with respect to a particular individual, such individual represents 8or intends the substance to have a stimulant, depressant or hallucinogenic 9effect on the central nervous system substantially similar to the stimulant, 10depressant or hallucinogenic effect on the central nervous system of a 11controlled substance included in the schedules designated in K.S.A. 65-124105 or 65-4107, and amendments thereto.13(2) "Controlled substance analog" does not include:14(A) A controlled substance;15(B) a substance for which there is an approved new drug application; 16or17(C) a substance with respect to which an exemption is in effect for 18investigational use by a particular person under section 505 of the federal 19food, drug, and cosmetic act, 21 U.S.C. § 355, to the extent conduct with 20respect to the substance is permitted by the exemption.21(c) "Cultivate" means the planting or promotion of growth of five or 22more plants that contain or can produce controlled substances.23(d) "Distribute" means the actual, constructive or attempted transfer 24from one person to another of some item whether or not there is an agency 25relationship. "Distribute" includes, but is not limited to, sale, offer for sale 26or any act that causes some item to be transferred from one person to 27another. "Distribute" does not include acts of administering, dispensing or 28prescribing a controlled substance as authorized by the pharmacy act of the 29state of Kansas, the uniform controlled substances act or otherwise 30authorized by law.31(e) (1) "Drug" means:32(A) Substances recognized as drugs in the official United States 33pharmacopeia, official homeopathic pharmacopoeia of the United States or 34official national formulary or any supplement to any of them;35(B) substances intended for use in the diagnosis, cure, mitigation, 36treatment or prevention of disease in humans or animals;37(C) substances, other than food, intended to affect the structure or any 38function of the body of humans or animals; and39(D) substances intended for use as a component of any article 40specified in subparagraph (A), (B) or (C).41(2) "Drug" does not include devices or their components, parts or 42accessories.43(f) (1) "Drug paraphernalia" means all equipment and materials of 1any kind that are used, or primarily intended or designed for use in 2planting, propagating, cultivating, growing, harvesting, manufacturing, 3compounding, converting, producing, processing, preparing, testing, 4analyzing, packaging, repackaging, storing, containing, concealing, 5injecting, ingesting, inhaling or otherwise introducing into the human body 6a controlled substance and in violation of this act.7(2) "Drug paraphernalia" includes, but is not limited to:8(A) Kits used or intended for use in planting, propagating, cultivating, 9growing or harvesting any species of plant that is a controlled substance or 10from which a controlled substance can be derived;11(B) kits used or intended for use in manufacturing, compounding, 12converting, producing, processing or preparing controlled substances;13(C) isomerization devices used or intended for use in increasing the 14potency of any species of plant that is a controlled substance;15(D) testing equipment used or intended for use in identifying or in 16analyzing the strength, effectiveness or purity of controlled substances;17(E) scales and balances used or intended for use in weighing or 18measuring controlled substances;19(F) diluents and adulterants, including, but not limited to, quinine 20hydrochloride, mannitol, mannite, dextrose and lactose that are used or 21intended for use in cutting controlled substances;22(G) separation gins and sifters used or intended for use in removing 23twigs and seeds from or otherwise cleaning or refining marijuana 24controlled substances;25(H) blenders, bowls, containers, spoons and mixing devices used or 26intended for use in compounding controlled substances;27(I) capsules, balloons, envelopes, bags and other containers used or 28intended for use in packaging small quantities of controlled substances;29(J) containers and other objects used or intended for use in storing or 30concealing controlled substances;31(K) hypodermic syringes, needles and other objects used or intended 32for use in parenterally injecting controlled substances into the human 33body;34(L) objects used or primarily intended or designed for use in 35ingesting, inhaling or otherwise introducing marijuana, cocaine, hashish, 36hashish oil, phencyclidine (PCP), methamphetamine or amphetamine into 37the human body, such as:38(i) Metal, wooden, acrylic, glass, stone, plastic or ceramic pipes with 39or without screens, permanent screens, hashish heads or punctured metal 40bowls;41(ii) water pipes, bongs or smoking pipes designed to draw smoke 42through water or another cooling device;43(iii) carburetion pipes, glass or other heat-resistant tubes or any other 1device used, intended to be used or designed to be used to cause 2vaporization of a controlled substance for inhalation;3(iv) smoking and carburetion masks;4(v) roach clips, objects used to hold burning material, such as a 5marijuana cigarette, that has become too small or too short to be held in 6the hand;7(vi) miniature cocaine spoons and cocaine vials;8(vii) chamber smoking pipes;9(viii) carburetor smoking pipes;10(ix) electric smoking pipes;11(x) air-driven smoking pipes;12(xi) chillums;13(xii) bongs;14(xiii) ice pipes or chillers;15(xiv) any smoking pipe manufactured to disguise its intended 16purpose;17(xv) wired cigarette papers; or18(xvi) cocaine freebase kits.19(3) "Drug paraphernalia" does not include:20(A) Any products, chemicals or materials described in K.S.A. 21-215709(a), and amendments thereto; or22(B) any materials used or intended for use to test a substance for the 23presence of fentanyl, a fentanyl analog, ketamine or gamma 24hydroxybutyric acid.25(g) "Fentanyl-related controlled substance" means any substance 26designated in K.S.A. 65-4105(b)(1), (b)(2), (b)(4), (b)(10), (b)(11), (b)27(12), (b)(15), (b)(16), (b)(17), (b)(20), (b)(21), (b)(24), (b)(26), (b)(27), (b)28(28), (b)(35), (b)(42), (b)(43), (b)(44), (b)(45), (b)(48), (b)(50), (b)(54), (b)29(55), (b)(56), (b)(57), (b)(58), (b)(59), (b)(68), (b)(70), (b)(71), (b)(72), (b)30(73), (b)(74), (b)(75), (b)(76), (b)(77), (b)(78), (b)(79), (b)(80), (b)(81), (b)31(82), (b)(83), (b)(84), (b)(85), (b)(91), (b)(97), (b)(98), (b)(99), (b)(103), 32(b)(104), (g)(1) or (g)(2) or 65-4107(c)(1), (c)(6), (c)(9), (c)(26), (c)(28), 33(c)(30), (f)(3)(A) or (f)(3)(B), and amendments thereto, or any analog 34thereof.35(h) "Immediate precursor" means a substance that the state board of 36pharmacy has found to be and by rules and regulations designates as being 37the principal compound commonly used or produced primarily for use and 38that is an immediate chemical intermediary used or likely to be used in the 39manufacture of a controlled substance, the control of which is necessary to 40prevent, curtail or limit manufacture.41(i) "Isomer" means all enantiomers and diastereomers.42(j) "Manufacture" means the production, preparation, propagation, 43compounding, conversion or processing of or placing into pill or capsule 1form a controlled substance either directly or indirectly or by extraction 2from substances of natural origin or independently by means of chemical 3synthesis or by a combination of extraction and chemical synthesis. 4"Manufacture" does not include:5(1) The preparation or compounding of a controlled substance by an 6individual for the individual's own lawful use or the preparation, 7compounding, packaging or labeling of a controlled substance:8(A) By a practitioner or the practitioner's agent pursuant to a lawful 9order of a practitioner as an incident to the practitioner's administering or 10dispensing of a controlled substance in the course of the practitioner's 11professional practice; or12(B) by a practitioner or by the practitioner's authorized agent under 13such practitioner's supervision for the purpose of or as an incident to 14research, teaching or chemical analysis or by a pharmacist or medical care 15facility as an incident to dispensing of a controlled substance; or16(2) the addition of diluents or adulterants, including, but not limited 17to, quinine hydrochloride, mannitol, mannite, dextrose or lactose that are 18intended for use in cutting a controlled substance.19(k) "Marijuana" means all parts of all varieties of the plant Cannabis 20whether growing or not, the seeds thereof, the resin extracted from any 21part of the plant and every compound, manufacture, salt, derivative, 22mixture or preparation of the plant, its seeds or resin. "Marijuana" does not 23include:24(1) The mature stalks of the plant, fiber produced from the stalks, oil 25or cake made from the seeds of the plant, any other compound, 26manufacture, salt, derivative, mixture or preparation of the mature stalks, 27except the resin extracted therefrom, fiber, oil or cake or the sterilized seed 28of the plant that is incapable of germination;29(2) any substance listed in schedules II through V of the uniform 30controlled substances act;31(3) drug products approved by the United States food and drug 32administration as of the effective date of this act;33(4) cannabidiol (other trade name: 2-[(3-methyl-6-(1-methylethenyl)-342-cyclohexen-1-yl]-5-pentyl-1,3-benzenediol); or35(5) industrial hemp as defined in K.S.A. 2-3901, and amendments 36thereto, when cultivated, produced, possessed or used for activities 37authorized by the commercial industrial hemp act.38(l) "Minor" means a person under 18 years of age.39(m)(l) "Narcotic drug" means any of the following whether produced 40directly or indirectly by extraction from substances of vegetable origin or 41independently by means of chemical synthesis or by a combination of 42extraction and chemical synthesis:43(1) Opium and opiate and any salt, compound, derivative or 1preparation of opium or opiate;2(2) any salt, compound, isomer, derivative or preparation thereof that 3is chemically equivalent or identical with any of the substances referred to 4in paragraph (1) but not including the isoquinoline alkaloids of opium;5(3) opium poppy and poppy straw;6(4) coca leaves and any salt, compound, derivative or preparation of 7coca leaves and any salt, compound, isomer, derivative or preparation 8thereof that is chemically equivalent or identical with any of these 9substances, but not including decocainized coca leaves or extractions of 10coca leaves that do not contain cocaine or ecgonine.11(n)(m) "Opiate" means any substance having an addiction-forming or 12addiction-sustaining liability similar to morphine or being capable of 13conversion into a drug having addiction-forming or addiction-sustaining 14liability. "Opiate" does not include, unless specifically designated as 15controlled under K.S.A. 65-4102, and amendments thereto, the 16dextrorotatory isomer of 3-methoxy-n-methylmorphinan and its salts 17(dextromethorphan). "Opiate" does include its racemic and levorotatory 18forms.19(o)(n) "Opium poppy" means the plant of the species Papaver 20somniferum l. except its seeds.21(p)(o) "Person" means an individual, corporation, government or 22governmental subdivision or agency, business trust, estate, trust, 23partnership, association or any other legal entity.24(q)(p) "Poppy straw" means all parts, except the seeds, of the opium 25poppy, after mowing.26(r)(q) "School property" means property upon which is located a 27structure used by a unified school district or an accredited nonpublic 28school for student instruction or attendance or extracurricular activities of 29pupils enrolled in kindergarten or any of the grades one through 12. This 30definition shall not be construed as requiring that school be in session or 31that classes are actually being held at the time of the offense or that 32children must be present within the structure or on the property during the 33time of any alleged criminal act. If the structure or property meets the 34above definition, the actual use of that structure or property at the time 35alleged shall not be a defense to the crime charged or the sentence 36imposed.37(s)(r) "Simulated controlled substance" means any product that 38identifies itself by a common name or slang term associated with a 39controlled substance and that indicates on its label or accompanying 40promotional material that the product simulates the effect of a controlled 41substance.42Sec. 14. K.S.A. 2025 Supp. 21-5705 is hereby amended to read as 43follows: 21-5705. (a) It shall be unlawful for any person to distribute or 1possess with the intent to distribute any of the following controlled 2substances or controlled substance analogs thereof:3(1) Opiates, opium or narcotic drugs, or any stimulant designated in 4K.S.A. 65-4107(d)(1), (d)(3) or (f)(1), and amendments thereto;5(2) any depressant designated in K.S.A. 65-4105(e), 65-4107(e), 65-64109(b) or (c) or 65-4111(b), and amendments thereto;7(3) any stimulant designated in K.S.A. 65-4105(f), 65-4107(d)(2), (d)8(4), (d)(5) or (f)(2) or 65-4109(e), and amendments thereto;9(4) any hallucinogenic drug designated in K.S.A. 65-4105(d), 65-104107(g) or 65-4109(g), and amendments thereto;11(5) any substance designated in K.S.A. 65-4105(g) or 65-4111(c), (d), 12(e), (f) or (g), and amendments thereto;13(6) any anabolic steroids as defined in K.S.A. 65-4109(f), and 14amendments thereto; or15(7) any substance designated in K.S.A. 65-4105(h), and amendments 16thereto.17(b) It shall be unlawful for any person to distribute or possess with 18the intent to distribute a controlled substance or a controlled substance 19analog designated in K.S.A. 65-4113, and amendments thereto.20(c) It shall be unlawful for any person to cultivate any controlled 21substance or controlled substance analog listed in subsection (a).22(d) (1) Except as provided further, violation of subsection (a) is a:23(A) Drug severity level 4 felony if the quantity of the material was 24less than 3.5 grams;25(B) drug severity level 3 felony if the quantity of the material was at 26least 3.5 grams but less than 100 grams;27(C) drug severity level 2 felony if the quantity of the material was at 28least 100 grams but less than 1 kilogram; and29(D) drug severity level 1 felony if the quantity of the material was 1 30kilogram or more.31(2) Except as provided further, violation of subsection (a) with 32respect to material containing any quantity of marijuana, or an analog 33thereof, is a:34(A) Drug severity level 4 felony if the quantity of the material was 35less than 25 grams;36(B) drug severity level 3 felony if the quantity of the material was at 37least 25 grams but less than 450 grams;38(C) drug severity level 2 felony if the quantity of the material was at 39least 450 grams but less than 30 kilograms; and40(D) drug severity level 1 felony if the quantity of the material was 30 41kilograms or more.42(3) Except as provided further, violation of subsection (a) with 43respect to material containing any quantity of a fentanyl-related controlled 1substance, heroin as defined by K.S.A. 65-4105(c)(12), and amendments 2thereto, or methamphetamine as defined by K.S.A. 65-4107(d)(3) or (f)(1), 3and amendments thereto, or an analog thereof, is a:4(A) Drug severity level 4 felony if the quantity of the material was 5less than 1 gram;6(B) drug severity level 3 felony if the quantity of the material was at 7least 1 gram but less than 3.5 grams;8(C) drug severity level 2 felony if the quantity of the material was at 9least 3.5 grams but less than 100 grams; and10(D) drug severity level 1 felony if the quantity of the material was 11100 grams or more.12(4)(3) Except as provided further, violation of subsection (a) with 13respect to material containing any quantity of a controlled substance 14designated in K.S.A. 65-4105, 65-4107, 65-4109 or 65-4111, and 15amendments thereto, or an analog thereof, distributed by dosage unit, is a:16(A) Drug severity level 4 felony if the number of dosage units was 17fewer than 10;18(B) drug severity level 3 felony if the number of dosage units was at 19least 10 but fewer than 100;20(C) drug severity level 2 felony if the number of dosage units was at 21least 100 but fewer than 1,000; and22(D) drug severity level 1 felony if the number of dosage units was 231,000 or more.24(5)(4) Violation of subsection (a) with respect to material containing 25any quantity of a fentanyl-related controlled substance, distributed by 26dosage unit, is a:27(A) Drug severity level 4 felony if the number of dosage units was 28fewer than 10;29(B) drug severity level 3 felony if the number of dosage units was at 30least 10 but fewer than 50;31(C) drug severity level 2 felony if the number of dosage units was at 32least 50 but fewer than 250; and33(D) drug severity level 1 felony if the number of dosage units was 34250 or more.35(6)(5) For any violation of subsection (a), the severity level of the 36offense shall be increased one level if the controlled substance or 37controlled substance analog was distributed or possessed with the intent to 38distribute on or within 1,000 feet of any school property.39(7)(6) Violation of subsection (b) is a:40(A) Class A person misdemeanor, except as provided in subsection 41(d)(7)(B); and42(B) nondrug severity level 7, person felony if the substance was 43distributed to or possessed with the intent to distribute to a minor.1(8)(7) Violation of subsection (c) is a:2(A) Drug severity level 3 felony if the number of plants cultivated 3was more than 4 but fewer than 50;4(B) drug severity level 2 felony if the number of plants cultivated was 5at least 50 but fewer than 100; and6(C) drug severity level 1 felony if the number of plants cultivated was 7100 or more.8(e) In any prosecution under this section, there shall be an inference 9of an intent to distribute if such an inference is supported by the facts and 10such person possesses the following quantities of controlled substances or 11analogs thereof:12(1) 450 grams or more of marijuana;13(2) 3.5 grams or more of a fentanyl-related controlled substance, 14heroin or methamphetamine;15(3)(2) 50 dosage units or more containing any quantity of a fentanyl-16related controlled substance;17(4)(3) 100 dosage units or more containing any other controlled 18substance; or19(5)(4) 100 grams or more of any other controlled substance.20(f) It shall not be a defense to charges arising under this section that 21the defendant:22(1) Was acting in an agency relationship on behalf of any other party 23in a transaction involving a controlled substance or controlled substance 24analog;25(2) did not know the quantity of the controlled substance or 26controlled substance analog; or27(3) did not know the specific controlled substance or controlled 28substance analog contained in the material that was distributed or 29possessed with the intent to distribute.30(g) As used in this section:31(1) "Material" means the total amount of any substance, including a 32compound or a mixture, which contains any quantity of a controlled 33substance or controlled substance analog.34(2) "Dosage unit" means a controlled substance or controlled 35substance analog distributed or possessed with the intent to distribute as a 36discrete unit, including, but not limited to, one pill, one capsule or one 37microdot, and not distributed by weight.38(A) For steroids, or controlled substances in liquid solution legally 39manufactured for prescription use, or an analog thereof, "dosage unit" 40means the smallest medically approved dosage unit, as determined by the 41label, materials provided by the manufacturer, a prescribing authority, 42licensed health care professional or other qualified health authority.43(B) For illegally manufactured controlled substances in liquid 1solution, or controlled substances in liquid products not intended for 2ingestion by human beings, or an analog thereof, "dosage unit" means 10 3milligrams, including the liquid carrier medium, except as provided in 4subsection (g)(2)(C).5(C) For lysergic acid diethylamide (LSD) in liquid form, or an analog 6thereof, a dosage unit is defined as 0.4 milligrams, including the liquid 7medium.8Sec. 15. K.S.A. 21-5706 is hereby amended to read as follows: 21-95706. (a) It shall be unlawful for any person to possess any opiates, opium 10or narcotic drugs, or any stimulant designated in K.S.A. 65-4107(d)(1), (d)11(3) or (f)(1), and amendments thereto, or a controlled substance analog 12thereof.13(b) It shall be unlawful for any person to possess any of the following 14controlled substances or controlled substance analogs thereof:15(1) Any depressant designated in K.S.A. 65-4105(e), 65-4107(e), 65-164109(b) or (c) or 65-4111(b), and amendments thereto;17(2) any stimulant designated in K.S.A. 65-4105(f), 65-4107(d)(2), (d)18(4), (d)(5) or (f)(2) or 65-4109(e), and amendments thereto;19(3) any hallucinogenic drug designated in K.S.A. 65-4105(d), 65-204107(g) or 65-4109(g), and amendments thereto;21(4) any substance designated in K.S.A. 65-4105(g) and 65-4111(c), 22(d), (e), (f) or (g), and amendments thereto;23(5) any anabolic steroids as defined in K.S.A. 65-4109(f), and 24amendments thereto;25(6) any substance designated in K.S.A. 65-4113, and amendments 26thereto; or27(7) any substance designated in K.S.A. 65-4105(h), and amendments 28thereto.29(c) (1) Violation of subsection (a) is a drug severity level 5 felony.30(2) Except as provided in subsection (c)(3):31 (A) Violation of subsection (b) is a class A nonperson misdemeanor, 32except as provided in subparagraph (B); and33(B) violation of subsection (b)(1) through (b)(5) or (b)(7) is a drug 34severity level 5 felony if that person has a prior conviction under such 35subsection, under K.S.A. 65-4162, prior to its repeal, under a substantially 36similar offense from another jurisdiction, or under any city ordinance or 37county resolution for a substantially similar offense if the substance 38involved was 3, 4-methylenedioxymethamphetamine (MDMA), marijuana 39as designated in K.S.A. 65-4105(d), and amendments thereto, or any 40substance designated in K.S.A. 65-4105(h), and amendments thereto, or an 41analog thereof.42(3) If the substance involved is marijuana, as designated in K.S.A. 4365-4105(d), and amendments thereto, or tetrahydrocannabinols, as 1designated in K.S.A. 65-4105(h), and amendments thereto, violation of 2subsection (b) is a:3(A) Class B nonperson misdemeanor, except as provided in 4subparagraphs (B) and (C);5(B) class A nonperson misdemeanor if that person has a prior 6conviction under such subsection, under K.S.A. 65-4162, prior to its 7repeal, under a substantially similar offense from another jurisdiction, or 8under any city ordinance or county resolution for a substantially similar 9offense; and10(C) drug severity level 5 felony if that person has two or more prior 11convictions under such subsection, under K.S.A. 65-4162, prior to its 12repeal, under a substantially similar offense from another jurisdiction, or 13under any city ordinance or county resolution for a substantially similar 14offense.15(d) It shall be an affirmative defense to prosecution under this section 16arising out of a person's possession of any cannabidiol treatment 17preparation if the person:18(1) Has a debilitating medical condition, as defined in K.S.A. 2025 19Supp. 65-6235, and amendments thereto, or is the parent or guardian of a 20minor child who has such debilitating medical condition;21(2) is possessing a cannabidiol treatment preparation, as defined in 22K.S.A. 2025 Supp. 65-6235, and amendments thereto, that is being used to 23treat such debilitating medical condition; and24(3) has possession of a letter, at all times while the person has 25possession of the cannabidiol treatment preparation, that:26(A) Shall be shown to a law enforcement officer on such officer's 27request;28(B) is dated within the preceding 15 months and signed by the 29physician licensed to practice medicine and surgery in Kansas who 30diagnosed the debilitating medical condition;31(C) is on such physician's letterhead; and32(D) identifies the person or the person's minor child as such 33physician's patient and identifies the patient's debilitating medical 34condition.35(e) It shall not be a defense to charges arising under this section that 36the defendant was acting in an agency relationship on behalf of any other 37party in a transaction involving a controlled substance or controlled 38substance analog.39Sec. 16. K.S.A. 21-5709 is hereby amended to read as follows: 21-405709. (a) It shall be unlawful for any person to possess ephedrine, 41pseudoephedrine, red phosphorus, lithium metal, sodium metal, iodine, 42anhydrous ammonia, pressurized ammonia or phenylpropanolamine, or 43their salts, isomers or salts of isomers with an intent to use the product to 1manufacture a controlled substance.2(b) It shall be unlawful for any person to use or possess with intent to 3use any drug paraphernalia to:4(1) Manufacture, cultivate, plant, propagate, harvest, test, analyze or 5distribute a controlled substance; or6(2) store, contain, conceal, inject, ingest, inhale or otherwise 7introduce a controlled substance into the human body.8(c) It shall be unlawful for any person to use or possess with intent to 9use anhydrous ammonia or pressurized ammonia in a container not 10approved for that chemical by the Kansas department of agriculture.11(d) It shall be unlawful for any person to purchase, receive or 12otherwise acquire at retail any compound, mixture or preparation 13containing more than 3.6 grams of pseudoephedrine base or ephedrine 14base in any single transaction or any compound, mixture or preparation 15containing more than nine grams of pseudoephedrine base or ephedrine 16base within any 30-day period.17(e) (1) Violation of subsection (a) is a drug severity level 3 felony;18(2) violation of subsection (b)(1) is a:(A)  drug severity level 5 19felony, except as provided in subsection (e)(2)(B); and20(B) class B nonperson misdemeanor if the drug paraphernalia was 21used to cultivate fewer than five marijuana plants;22(3) violation of subsection (b)(2) is a class B nonperson 23misdemeanor;24(4) violation of subsection (c) is a drug severity level 5 felony; and25(5) violation of subsection (d) is a class A nonperson misdemeanor.26(f) For persons arrested and charged under subsection (a) or (c), bail 27shall be at least $50,000 cash or surety, and such person shall not be 28released upon the person's own recognizance pursuant to K.S.A. 22-2802, 29and amendments thereto, unless the court determines, on the record, that 30the defendant is not likely to reoffend, the court imposes pretrial 31supervision or the defendant agrees to participate in a licensed or certified 32drug treatment program.33Sec. 17. K.S.A. 2025 Supp. 65-4101 is hereby amended to read as 34follows: 65-4101. As used in this act:35(a) "Administer" means the direct application of a controlled 36substance, whether by injection, inhalation, ingestion or any other means, 37to the body of a patient or research subject by:38(1) A practitioner or pursuant to the lawful direction of a practitioner; 39or40(2) the patient or research subject at the direction and in the presence 41of the practitioner.42(b) "Agent" means an authorized person who acts on behalf of or at 43the direction of a manufacturer, distributor or dispenser. "Agent" does not 1include a common carrier, public warehouseman or employee of the carrier 2or warehouseman.3(c) "Application service provider" means an entity that sells 4electronic prescription or pharmacy prescription applications as a hosted 5service where the entity controls access to the application and maintains 6the software and records on its server.7(d) "Board" means the state board of pharmacy.8(e) "Bureau" means the bureau of narcotics and dangerous drugs, 9United States department of justice, or its successor agency.10(f) "Controlled substance" means any drug, substance or immediate 11precursor included in any of the schedules designated in K.S.A. 65-4105, 1265-4107, 65-4109, 65-4111 and 65-4113, and amendments thereto.13(g) (1) "Controlled substance analog" means a substance that is 14intended for human consumption, and at least one of the following:15(A) The chemical structure of the substance is substantially similar to 16the chemical structure of a controlled substance listed in or added to the 17schedules designated in K.S.A. 65-4105 or 65-4107, and amendments 18thereto;19(B) the substance has a stimulant, depressant or hallucinogenic effect 20on the central nervous system substantially similar to the stimulant, 21depressant or hallucinogenic effect on the central nervous system of a 22controlled substance included in the schedules designated in K.S.A. 65-234105 or 65-4107, and amendments thereto; or24(C) with respect to a particular individual, such individual represents 25or intends the substance to have a stimulant, depressant or hallucinogenic 26effect on the central nervous system substantially similar to the stimulant, 27depressant or hallucinogenic effect on the central nervous system of a 28controlled substance included in the schedules designated in K.S.A. 65-294105 or 65-4107, and amendments thereto.30(2) "Controlled substance analog" does not include:31(A) A controlled substance;32(B) a substance for which there is an approved new drug application; 33or34(C) a substance with respect to which an exemption is in effect for 35investigational use by a particular person under section 505 of the federal 36food, drug and cosmetic act, 21 U.S.C. § 355, to the extent conduct with 37respect to the substance is permitted by the exemption.38(h) "Counterfeit substance" means a controlled substance that, or the 39container or labeling of which, without authorization bears the trademark, 40trade name or other identifying mark, imprint, number or device or any 41likeness thereof of a manufacturer, distributor or dispenser other than the 42person who in fact manufactured, distributed or dispensed the substance.43(i) "Cultivate" means the planting or promotion of growth of five or 1more plants that contain or can produce controlled substances.2(j) "DEA" means the U.S. department of justice, drug enforcement 3administration.4(k) "Deliver" or "delivery" means the actual, constructive or 5attempted transfer from one person to another of a controlled substance, 6whether or not there is an agency relationship.7(l) "Dispense" means to deliver a controlled substance to an ultimate 8user or research subject by or pursuant to the lawful order of a practitioner, 9including the packaging, labeling or compounding necessary to prepare the 10substance for that delivery, or pursuant to the prescription of a mid-level 11practitioner.12(m) "Dispenser" means a practitioner or pharmacist who dispenses, or 13a physician assistant who has authority to dispense prescription-only drugs 14in accordance with K.S.A. 65-28a08(b), and amendments thereto.15(n) "Distribute" means to deliver other than by administering or 16dispensing a controlled substance.17(o) "Distributor" means a person who distributes.18(p) (1) "Drug" means substances:19(A) Recognized as drugs in the official United States pharmacopeia, 20official homeopathic pharmacopoeia of the United States or official 21national formulary or any supplement to any of them thereto;22(B) intended for use in the diagnosis, cure, mitigation, treatment or 23prevention of disease in human or animals;24(C) other than food intended to affect the structure or any function of 25the body of human or animals; and26(D) intended for use as a component of any article specified in 27subparagraph (A), (B) or (C).28(2) "Drug" does not include devices or their components, parts or 29accessories.30(q) "Immediate precursor" means a substance that the board has 31found to be and by rule and regulation designates as being the principal 32compound commonly used or produced primarily for use and that is an 33immediate chemical intermediary used or likely to be used in the 34manufacture of a controlled substance, the control of which is necessary to 35prevent, curtail or limit manufacture.36(r) "Electronic prescription" means an electronically prepared 37prescription that is authorized and transmitted from the prescriber to the 38pharmacy by means of electronic transmission.39(s) "Electronic prescription application" means software that is used 40to create electronic prescriptions and that is intended to be installed on the 41prescriber's computers and servers where access and records are controlled 42by the prescriber.43(t) "Electronic signature" means a confidential personalized digital 1key, code, number or other method for secure electronic data transmissions 2that identifies a particular person as the source of the message, 3authenticates the signatory of the message and indicates the person's 4approval of the information contained in the transmission.5(u) "Electronic transmission" means the transmission of an electronic 6prescription, formatted as an electronic data file, from a prescriber's 7electronic prescription application to a pharmacy's computer, where the 8data file is imported into the pharmacy prescription application.9(v) "Electronically prepared prescription" means a prescription that is 10generated using an electronic prescription application.11(w) "Facsimile transmission" or "fax transmission" means the 12transmission of a digital image of a prescription from the prescriber or the 13prescriber's agent to the pharmacy. "Facsimile transmission" includes, but 14is not limited to, transmission of a written prescription between the 15prescriber's fax machine and the pharmacy's fax machine;, transmission of 16an electronically prepared prescription from the prescriber's electronic 17prescription application to the pharmacy's fax machine, computer or 18printer; or transmission of an electronically prepared prescription from the 19prescriber's fax machine to the pharmacy's fax machine, computer or 20printer.21(x) "Intermediary" means any technology system that receives and 22transmits an electronic prescription between the prescriber and the 23pharmacy.24(y) "Isomer" means all enantiomers and diastereomers.25(z) "Manufacture" means the production, preparation, propagation, 26compounding, conversion or processing of a controlled substance either 27directly or indirectly or by extraction from substances of natural origin or 28independently by means of chemical synthesis or by a combination of 29extraction and chemical synthesis and includes any packaging or 30repackaging of the substance or labeling or relabeling of its container, 31except that this term does not include the preparation or compounding of a 32controlled substance by an individual for the individual's own lawful use 33or the preparation, compounding, packaging or labeling of a controlled 34substance:35(1) By a practitioner or the practitioner's agent pursuant to a lawful 36order of a practitioner as an incident to the practitioner's administering or 37dispensing of a controlled substance in the course of the practitioner's 38professional practice; or39(2) by a practitioner or by the practitioner's authorized agent under 40such practitioner's supervision for the purpose of or as an incident to 41research, teaching or chemical analysis or by a pharmacist or medical care 42facility as an incident to dispensing of a controlled substance.43(aa) "Marijuana" means all parts of all varieties of the plant Cannabis 1whether growing or not, the seeds thereof, the resin extracted from any 2part of the plant and every compound, manufacture, salt, derivative, 3mixture or preparation of the plant, its seeds or resin. It does not include:4(1) The mature stalks of the plant, fiber produced from the stalks, oil 5or cake made from the seeds of the plant, any other compound, 6manufacture, salt, derivative, mixture or preparation of the mature stalks, 7except the resin extracted therefrom, fiber, oil or cake or the sterilized seed 8of the plant that is incapable of germination;9(2) any substance listed in schedules II through V of the uniform 10controlled substances act;11(3) drug products approved by the United States food and drug 12administration as of the effective date of this act;13(4) cannabidiol (other trade name: 2-[(3-methyl-6-(1-methylethenyl)-142-cyclohexen-1-yl]-5-pentyl-1,3-benzenediol); or15(5) industrial hemp as defined in K.S.A. 2-3901, and amendments 16thereto, when cultivated, produced, possessed or used for activities 17authorized by the commercial industrial hemp act.18(bb) "Medical care facility" shall have the meaning ascribed to that 19term in K.S.A. 65-425, and amendments thereto.20(cc)(bb) "Mid-level practitioner" means a certified nurse-midwife 21engaging in the independent practice of midwifery under the independent 22practice of midwifery act, an advanced practice registered nurse issued a 23license pursuant to K.S.A. 65-1131, and amendments thereto, who has 24authority to prescribe drugs under K.S.A. 65-1130, and amendments 25thereto, or a physician assistant licensed under the physician assistant 26licensure act who has authority to prescribe drugs pursuant to a written 27agreement with a supervising physician under K.S.A. 65-28a08, and 28amendments thereto.29(dd)(cc) "Narcotic drug" means any of the following whether 30produced directly or indirectly by extraction from substances of vegetable 31origin or independently by means of chemical synthesis or by a 32combination of extraction and chemical synthesis:33(1) Opium and opiate and any salt, compound, derivative or 34preparation of opium or opiate;35(2) any salt, compound, isomer, derivative or preparation thereof that 36is chemically equivalent or identical with any of the substances referred to 37in paragraph (1) but not including the isoquinoline alkaloids of opium;38(3) opium poppy and poppy straw;39(4) coca leaves and any salt, compound, derivative or preparation of 40coca leaves, and any salt, compound, isomer, derivative or preparation 41thereof that is chemically equivalent or identical with any of these 42substances, but not including decocainized coca leaves or extractions of 43coca leaves that do not contain cocaine or ecgonine.1(ee)(dd) "Opiate" means any substance having an addiction-forming 2or addiction-sustaining liability similar to morphine or being capable of 3conversion into a drug having addiction-forming or addiction-sustaining 4liability. It "Opiate" does not include, unless specifically designated as 5controlled under K.S.A. 65-4102, and amendments thereto, the 6dextrorotatory isomer of 3-methoxy-n-methylmorphinan and its salts 7(dextromethorphan). It does include its racemic and levorotatory forms.8(ff)(ee) "Opium poppy" means the plant of the species Papaver 9somniferum l. except its seeds.10(gg)(ff) "Person" means an individual, corporation, government, or 11governmental subdivision or agency, business trust, estate, trust, 12partnership or association or any other legal entity.13(hh)(gg) "Pharmacist" means any natural person licensed under 14K.S.A. 65-1625 et seq., and amendments thereto, to practice pharmacy.15(ii)(hh) "Pharmacist intern" means: (1) A student currently enrolled in 16an accredited pharmacy program; (2) a graduate of an accredited pharmacy 17program serving such person's internship; or (3) a graduate of a pharmacy 18program located outside of the United States that is not accredited and who 19had successfully passed equivalency examinations approved by the board.20(jj)(ii) "Pharmacy prescription application" means software that is 21used to process prescription information, is installed on a pharmacy's 22computers and servers, and is controlled by the pharmacy.23(kk)(jj) "Poppy straw" means all parts, except the seeds, of the opium 24poppy, after mowing.25(ll)(kk) "Practitioner" means a person licensed to practice medicine 26and surgery, dentist, podiatrist, veterinarian, optometrist, or scientific 27investigator or other person authorized by law to use a controlled 28substance in teaching or chemical analysis or to conduct research with 29respect to a controlled substance.30(mm)(ll) "Prescriber" means a practitioner or a mid-level practitioner.31(nn)(mm) "Production" includes the manufacture, planting, 32cultivation, growing or harvesting of a controlled substance.33(oo)(nn) "Readily retrievable" means that records kept by automatic 34data processing applications or other electronic or mechanized 35recordkeeping systems can be separated out from all other records within a 36reasonable time not to exceed 48 hours of a request from the board or 37other authorized agent or that hard-copy records are kept on which certain 38items are asterisked, redlined or in some other manner visually identifiable 39apart from other items appearing on the records.40(pp)(oo) "Ultimate user" means a person who lawfully possesses a 41controlled substance for such person's own use or for the use of a member 42of such person's household or for administering to an animal owned by 43such person or by a member of such person's household.1Sec. 18. K.S.A. 2025 Supp. 65-4105 is hereby amended to read as 2follows: 65-4105. (a) The controlled substances listed in this section are 3included in schedule I and the number set forth opposite each drug or 4substance is the DEA controlled substances code that has been assigned to 5it.6(b) Any of the following opiates, including their isomers, esters, 7ethers, salts, and salts of isomers, esters and ethers, unless specifically 8excepted, whenever the existence of these isomers, esters, ethers and salts 9is possible within the specific chemical designation:10(1) Acetyl fentanyl11(N-(1-phenethylpiperidin-4-yl)-N-phenylacetamide) 982112(2) Acetyl-alpha-methylfentanyl (N-[1-(1-methyl-2-phenethyl)-4-13piperidinyl]-N-phenylacetamide) 981514(3) Acetylmethadol 960115(4) Acryl fentanyl (N-(1-phenethylpiperidin-4-yl)-N-16phenylacrylamide; acryloylfentanyl) 981117(5) AH-7921 (3,4-dichloro-N-[(1-18dimethylamino)cyclohexylmethyl]benzamide) 955119(6) Allylprodine 960220(7) Alphacetylmethadol 960321(except levo-alphacetylmethadol also known as levo-alpha-22acetylmethadol, levomethadyl acetate or LAAM)23(8) Alphameprodine 960424(9) Alphamethadol 960525(10) Alpha′-methyl butyryl fentanyl (2-methyl-N-(1-26phenethylpiperidin-4-yl)-N-phenylbutanamide) 986427(11) Alpha-methylfentanyl (N-[1-(alpha-methyl-beta-phenyl)ethyl-4-28piperidyl] propionanilide; 1-(1-methyl-2-phenylethyl)-4-(N-propanilido) 29piperidine) 981430(12) Alpha-methylthiofentanyl (N-[1-methyl-2-(2-thienyl)ethyl-4-31piperidinyl]-N-phenylpropanamide) 983232(13) Benzethidine 960633(14) Betacetylmethadol 960734(15) Beta-hydroxyfentanyl (N-[1-(2-hydroxy-2-phenethyl)-4-35piperidinyl]-N-phenylpropanamide) 983036(16) Beta-hydroxy-3-methylfentanyl (other name: N-[1-(2-hydroxy-2-37phenethyl)-3-methyl-4-piperidinyl]-N-phenylpropanamide) 983138(17) Beta-hydroxythiofentanyl (N-[1-[2-hydroxy-2-(thiophen-2-39yl)ethyl]piperidin-4-yl]-N-phenylpropionamide) 983640(18) Betameprodine 960841(19) Betamethadol 960942(20) Beta-methyl fentanyl (N-phenyl-N-(1-(2-phenylpropyl)piperidin-434-yl)propionamide; also known as β-methyl fentanyl) 98561(21) Beta'-phenyl fentanyl (N-(1-phenethylpiperidin-4-yl)-N, 3-2diphenylpropanamide; also known as β'-phenyl fentanyl; 3-3phenylpropanoyl fentanyl) 98424(22) Betaprodine 96115(23) Brorphine (1-(1-(1-(4-bromophenyl)ethyl)piperidin-4-yl)-1,3-6dihydro-2H-benzo[d]imidazol-2-one) 90987(24) Butyryl fentanyl (N-(1-phenethylpiperidin-4-yl)-N-8phenylbutyramide) 98229(25) Clonitazene 961210(26) Crotonyl fentanyl ((E)-N-(1-phenethylpiperidin-4-yl)-N-11phenylbut-2-enamide) 984412(27) Cyclopentyl fentanyl (N-(1-phenethylpiperidin-4-yl)-N-13phenylcyclopentanecarboxamide) 984714(28) Cyclopropyl fentanyl (N-(1-phenethylpiperidin-4-yl)-N-15phenylcyclopropanecarboxamide) 984516(29) Dextromoramide 961317(30) Diampromide 961518(31) Diethylthiambutene 961619(32) Difenoxin 916820(33) Dimenoxadol 961721(34) Dimepheptanol 961822(35) 2′,5′-Dimethoxyfentanyl (N-(1-(2,5-23dimethoxyphenethyl)piperidin-4-yl)-N-phenylpropionamide) 986124(36) Dimethylthiambutene 961925(37) Dioxaphetyl butyrate 962126(38) Dipipanone 962227(39) Ethylmethylthiambutene 962328(40) Etonitazene 962429(41) Etoxeridine 962530(42) Fentanyl carbamate (ethyl (1-phenethylpiperidin-4-yl)31(phenyl)carbamate) 985132(43) 2′-Fluoro ortho-fluorofentanyl (N-(1-(2-33fluorophenethyl)piperidin-4-yl)-N-(2-fluorophenyl)propionamide; also 34known as 2′-fluoro 2-fluorofentanyl) 985535(44) Furanyl fentanyl (N-(1-phenethylpiperidin-4-yl)-N-phenylfuran-362-carboxamide) 983437(45) 3-Furanyl fentanyl (N-(1-phenethylpiperidin-4-yl)-N-38phenylfuran-3-carboxamide) 986039(46) Furethidine 962640(47) Hydroxypethidine 962741(48) Isobutyryl fentanyl (N-(1-phenethylpiperidin-4-yl)-N-42phenylisobutyramide) 982743(49) Isotonitazene (N,N-diethyl-2-(2-(4 isopropoxybenzyl)-5-nitro-11H-benzimidazol-1-yl)ethan-1-amine; N,N-diethyl-2-[[4-(1-2methylethoxy)phenyl]methyl]-5-nitro-1 H-benzimidazole-1-ethanamine)3 96144(50) Isovaleryl fentanyl (3-methyl- N -(1-phenethylpiperidin-4-yl)-5N-phenylbutanamide) 98626(51) Ketobemidone 96287(52) Levomoramide 96298(53) Levophenacylmorphan 96319(54) Meta -Fluorofentanyl (N -(3-fluorophenyl)- N -(1-10phenethylpiperidin-4-yl)propionamide) 985711(55) Meta -Fluoroisobutyryl fentanyl ( N -(3-fluorophenyl)- N -(1-12phenethylpiperidin-4-yl)isobutyramide) 985813(56) Methoxyacetyl fentanyl (2-methoxy-N-(1-phenethylpiperidin-4-14yl)-N-phenylacetamide) 982515(57) 4′-Methyl acetyl fentanyl (N-(1-(4-methylphenethyl)piperidin-4-16yl)-N-phenylacetamide) 981917(58) 3-Methylfentanyl (N-[3-methyl-1-(2-phenylethyl)-4-piperidyl]-N-18phenylpropanamide) 981319(59) 3-Methylthiofentanyl (N-[(3-methyl-1-(2-thienyl)ethyl-4-20piperidinyl]-N-phenylpropanamide) 983321(60) Metonitazene (N,N-diethyl-2-(2-(4-methoxybenzyl)-5-nitro-1H-22benzimidazol-1-yl)ethan-1-amine) 975723(61) Morpheridine 963224(62) MPPP (1-methyl-4-phenyl-4-propionoxypiperidine) 966125(63) MT-45 (1-cychohexyl-4-(1,2-diphenylethyl)piperazine)26 956027(64) Noracymethadol 963328(65) Norlevorphanol 963429(66) Normethadone 963530(67) Norpipanone 963631(68) Ocfentanil (N-(2-fluorophenyl)-2-methoxy-N-(1-32phenethylpiperidin-4-yl) acetamide) 983833(69) O-desmethyltramadol (Some trade or other names: 2-34((dimethylamino)methyl-1-(3-hydroxyphenyl)cyclohexanol;3-(2-35((dimethylamino)methyl)-1-hydroxycyclohexyl)phenol)36(70) Ortho-fluoroacryl fentanyl (N-(2-fluorophenyl)-N-(1-37phenethylpiperidin-4-yl)acrylamide) 985238(71) Ortho-fluorobutyryl fentanyl (N-(2-fluorophenyl)-N-(1-39phenethylpiperidin-4-yl)butyramide; also known as 2-fluorobutyryl 40fentanyl) 984641(72) Ortho-fluorofentanyl (N-(2-fluorophenyl)-N-(1-42phenethylpiperidin-4-yl)propionamide; 2-fluorofentanyl) 981643(73) Ortho -Fluorofuranyl fentanyl ( N -(2-fluorophenyl)- N -(1-1phenethylpiperidin-4-yl)furan-2-carboxamide) 98632(74) (Ortho-fluoroisobutyryl fentanyl (N-(2-fluorophenyl)-N-(1-3phenethylpiperidin-4-yl)isobutyramide) 98534(75) Ortho-methyl acetylfentanyl (N-(2-methylphenyl)-N-(1-5phenethylpiperidin-4-yl)acetamide; also known as 2-methyl 6acetylfentanyl) 98487(76) Ortho-methyl methoxyacetyl fentanyl (2-methoxy-N-(2-8methylphenyl)-N-(1-phenethylpiperidin-4-yl)acetamide; also known as 2-9methyl methoxyacetyl10 fentanyl) 982011(77) Para-chloroisobutyryl fentanyl (N-(4-chlorophenyl)-N-(1-12phenethylpiperidin-4-yl)isobutyramide) 982613(78) Para-fluorobutyryl fentanyl (N-(4-fluorophenyl)-N-(1-14phenethylpiperidin-4-yl)butyramide) 982315(79) Para-fluorofentanyl (N-(4-fluorophenyl)-N-[1-(2-phenethyl)-4-16piperidinyl]propanamide) 981217(80) Para-fluoroisobutyryl fentanyl (N-(4-fluorophenyl)-N-(1-18phenethylpiperidin-4-yl)isobutyramide, 4-fluoroisobutyryl fentanyl)19 982420(81) Para-fluoro furanyl fentanyl (N-(4-fluorophenyl)-N-(1-21phenethylpiperidin-4-yl)furan-2-carboxamide) 985422(82) Para-methoxybutyryl fentanyl (N-(4-methoxyphenyl)-N-(1-23phenethylpiperidin-4-yl)butyramide) 983724(83) Para -Methoxyfuranyl fentanyl ( N -(4-methoxyphenyl)- N -(1-25phenethylpiperidin-4-yl)furan-2-carboxamide 985926(84) para -Methylcyclopropyl fentanyl ( N -(4-methylphenyl)- N -(1-27phenethylpiperidin-4-yl)cyclopropanecarboxamide) 986528(85) Para-methylfentanyl (N-(4-methylphenyl)-N-(1-29phenethylpiperidin-4-yl)propionamide; also known as 4-methylfentanyl)30 981731(86) PEPAP (1-(-2-phenethyl)-4-phenyl-4-acetoxypiperidine)32 966333(87) Phenadoxone 963734(88) Phenampromide 963835(89) Phenomorphan 964736(90) Phenoperidine 964137(91) Phenyl fentanyl (N-(1-phenethylpiperidin-4-yl)-N-38phenylbenzamide; also known as benzoyl fentanyl) 984139(92) Piritramide 964240(93) Proheptazine 964341(94) Properidine 964442(95) Propiram 964943(96) Racemoramide 96451(97) Tetrahydrofuranyl fentanyl (N-(1-phenethylpiperidin-4-yl)-N-2phenyltetrahydrofuran-2-carboxamide) 98433(98) Thiofentanyl (N-phenyl-N-[1-(2-thienyl)ethyl-4-piperidinyl]-4propanamide) 98355(99) Thiofuranyl fentanyl (N-(1-phenethylpiperidin-4-yl)-N-6phenylthiophene-2-carboxamide; also known as 2-thiofuranyl fentanyl; 7thiophene fentanyl) 98398(100) Tilidine 97509(101) Trimeperidine 964610(102) U-47700 (3,4-dichloro-N-[2-(dimethylamino)cyclohexyl]-N-11methylbenzamide) 954712(103) Valeryl fentanyl (N-(1-phenethylpiperidin-4-yl)-N-13phenylpentanamide) 984014(104) Zipeprol (1-methoxy-3-[4-(2-methoxy-2-phenylethyl)piperazin-1-15yl]-1-phenylpropan-2-ol) 987316(c) Any of the following opium derivatives, their salts, isomers and 17salts of isomers, unless specifically excepted, whenever the existence of 18these salts, isomers and salts of isomers is possible within the specific 19chemical designation:20(1) Acetorphine 931921(2) Acetyldihydrocodeine 905122(3) Benzylmorphine 905223(4) Codeine methylbromide 907024(5) Codeine-N-Oxide 905325(6) Cyprenorphine 905426(7) Desomorphine 905527(8) Dihydromorphine 914528(9) Drotebanol 933529(10) Etorphine (except hydrochloride salt) 905630(11) Heroin 920031(12) Hydromorphinol 930132(13) Methyldesorphine 930233(14) Methyldihydromorphine 930434(15) Morphine methylbromide 930535(16) Morphine methylsulfonate 930636(17) Morphine-N-Oxide 930737(18) Myrophine 930838(19) Nicocodeine 930939(20) Nicomorphine 40(21) Normorphine 931341(22) Pholcodine 931442(23) Thebacon 931543(d) Any material, compound, mixture or preparation that contains any 1quantity of the following hallucinogenic substances, their salts, isomers 2and salts of isomers, unless specifically excepted, whenever the existence 3of these salts, isomers and salts of isomers is possible within the specific 4chemical designation:5(1) Alpha-ethyltryptamine 72496Some trade or other names: etryptamine; Monase; α-ethyl-1H-indole-3-7ethanamine; 3-(2-aminobutyl) indole; α-ET; and AET.8(2) 4-bromo-2,5-dimethoxy-amphetamine 73919Some trade or other names: 4-bromo-2,5-dimethoxy-alpha-10methylphenethylamine; 4-bromo-2,5-DMA.11(3) 2,5-dimethoxyamphetamine 739612Some trade or other names: 2,5-dimethoxy-alpha-methyl-phenethylamine; 132,5-DMA.14(4) 4-methoxyamphetamine 741115Some trade or other names: 4-methoxy-alpha-methylphene-thylamine; 16paramethoxyamphetamine; PMA.17(5) 5-methoxy-3,4-methylenedioxy-amphetamine 740118(6) 4-methyl-2,5-dimethoxy-amphetamine 739519Some trade or other names: 4-methyl-2,5-dimethoxy-alpha-20methylphenethylamine; "DOM"; and "STP".21(7) 3,4-methylenedioxy amphetamine 740022(8) 3,4-methylenedioxymethamphetamine (MDMA) 740523(9) 3,4-methylenedioxy-N-ethylamphetamine (also known as N-24ethyl-alpha-methyl-3,4 (methylenedioxy) phenethylamine, N-ethyl MDA, 25MDE, and MDEA) 740426(10) N-hydroxy-3,4-methylenedioxyamphetamine (also known as N-27hydroxy-alpha-methyl-3,4-(methylenedioxy) phenethylamine, and N-28hydroxy MDA) 740229(11) 3,4,5-trimethoxy amphetamine 739030(12) Bufotenine 743331Some trade or other names: 3-(Beta-Dimethylaminoethyl)-5-32hydroxyindole; 3-(2-dimethylaminoethyl)-5-indolol; N, N-33dimethylserotonin; 5-hydroxy-N,N-dimethyltryptamine; mappine.34(13) Diethyltryptamine 743435Some trade or other names: N,N-Diethyltryptamine; DET.36(14) Dimethyltryptamine 743537Some trade or other names: DMT.38(15) Ibogaine 726039Some trade or other names: 7-Ethyl-6,6 Beta,7,8,9,10,12,13-octahydro-2-40methoxy-6,9-methano-5H-pyrido[1',2':1,2]azepino[5,4-b]indole; 41Tabernanthe iboga42(16) Lysergic acid diethylamide 731543(17) Marijuana 73601(18)(17) Mescaline 73812(19)(18) Parahexyl 73743Some trade or other names: 3-Hexyl-l-hydroxy-7,8,9,10-tetrahydro-6,6,9-4trimethyl-6H-dibenzo[b,d]pyran; Synhexyl.5(20)(19) Peyote 74156Meaning all parts of the plant presently classified botanically as 7Lophophora williamsii Lemaire, whether growing or not, the seeds 8thereof, any extract from any part of such plant, and every compound, 9manufacture, salts, derivative, mixture or preparation of such plant, its 10seeds or extracts.11(21)(20) N-ethyl-3-piperidyl benzilate 748212(22)(21) N-methyl-3-piperidyl benzilate 748413(23)(22) Psilocybin 743714(24)(23) Psilocyn 743815Some trade or other names: Psilocin.16(25)(24) Ethylamine analog of phencyclidine 745517Some trade or other names: N-ethyl-1-phenyl-cyclo-hexylamine; (1-18phenylcyclohexyl)ethylamine; N-(1-phenylcyclohexyl)ethylamine; 19cyclohexamine; PCE.20(26)(25) Pyrrolidine analog of phencyclidine 745821Some trade or other names: 1-(1-phenylcyclohexyl)-pyrrolidine; PCPy; 22PHP.23(27)(26) Thiophene analog of phencyclidine 747024Some trade or other names: 1-[1-(2-thienyl)-cyclohexyl]-piperidine; 2-25thienyl analog of phencyclidine; TPCP; TCP.26(28)(27) 1-[1-(2-thienyl)-cyclohexyl] pyrrolidine 747327Some other names: TCPy.28(29)(28) 2,5-dimethoxy-4-ethylamphetamine 739929Some trade or other names: DOET.30(30)(29) Salvia divinorum or salvinorum A; all parts of the plant presently 31classified botanically as salvia divinorum, whether growing or not, the 32seeds thereof, any extract from any part of such plant, and every 33compound, manufacture, salts, derivative, mixture or preparation of such 34plant, its seeds or extracts.35(31)(30) Datura stramonium, commonly known as gypsum weed or jimson 36weed; all parts of the plant presently classified botanically as datura 37stramonium, whether growing or not, the seeds thereof, any extract from 38any part of such plant, and every compound, manufacture, salts, derivative, 39mixture or preparation of such plant, its seeds or extracts.40(32)(31) 1-(3-[trifluoromethylphenyl])piperazine41Some trade or other names: TFMPP.42(33)(32) 4-Bromo-2,5-dimethoxyphenethylamine 739243(34)(33) 2,5-dimethoxy-4-(n)-propylthiophenethylamine (2C-T-7), its 1optical isomers, salts and salts of optical isomers 73482(35)(34) Alpha-methyltryptamine (other name: AMT) 74323(36)(35) 5-methoxy-N,N-diisopropyltryptamine (5-MeO-DIPT), its 4isomers, salts and salts of isomers 74395(37)(36) 2-(2,5-Dimethoxy-4-ethylphenyl)ethanamine (2C-E) 75096(38)(37) 2-(2,5-Dimethoxy-4-methylphenyl)ethanamine (2C-D)7 75088(39)(38) 2-(4-Chloro-2,5-dimethoxyphenyl)ethanamine (2C-C)9 751910(40)(39) 2-(4-Iodo-2,5-dimethoxyphenyl)ethanamine (2C-I) 751811(41)(40) 2-[4-(Ethylthio)-2,5-dimethoxyphenyl]ethanamine (2C-T-2)12 738513(42)(41) 2-[4-(Isopropylthio)-2,5-dimethoxyphenyl]14ethanamine (2C-T-4) 753215(43)(42) 2-(2,5-Dimethoxyphenyl)ethanamine (2C-H) 751716(44)(43) 2-(2,5-Dimethoxy-4-nitrophenyl)ethanamine (2C-N) 752117(45)(44) 2-(2,5-Dimethoxy-4-(n)-propylphenyl)ethanamine (2C-P)18 752419(46)(45) 5–methoxy–N,N–dimethyltryptamine (5–MeO–DMT)20 743121Some trade or other names: 5–methoxy–3–[2–(dimethylamino) 22ethyl]indole.23(47)(46) 2–(4–iodo–2,5–dimethoxyphenyl)–N–(2–24methoxybenzyl)ethanamine 753825Some trade or other names: 25I–NBOMe; 2C–I–NBOMe; 25I; Cimbi–5.26(48)(47) 2–(4–chloro–2,5–dimethoxyphenyl)–N–(2–27methoxybenzyl)ethanamine 753728Some trade or other names: 25C–NBOMe; 2C–C–NBOMe; 25C; Cimbi–2982.30(49)(48) 2–(4–bromo–2,5–dimethoxyphenyl)–N–(2–31methoxybenzyl)ethanamine 753632Some trade or other names: 25B–NBOMe; 2C–B–NBOMe; 25B; Cimbi–3336.34(50)(49) 2-(2,5-dimethoxyphenyl)-N-(2-methoxybenzyl)ethanamine35Some trade or other names: 25H-NBOMe.36(51)(50) 2-(2,5-dimethoxy-4-methylphenyl)-N-(2-37methoxybenzyl)ethanamine38Some trade or other names: 25D-NBOMe; 2C-D-NBOMe.39(52)(51) 2-(2,5-dimethoxy-4-nitrophenyl)-N-(2-40methoxybenzyl)ethanamine41Some trade or other names: 25N-NBOMe, 2C-N-NBOMe.42(53)(52) 1-(5-fluoropentyl)-N-(2-phenylpropan-2-yl)-1 H-pyrrolo[2,3-43b]pyridine-3-carboxamide (5F-CUMYL-P7AICA) 70851(54)(53) 2-(ethylamino)-2-(3-methoxyphenyl)cyclohexan-1-one (other 2names: methoxetamine, MXE) 72863(55)(54) 1-(4-methoxyphenyl)-N-methylpropan-2-amine (other names: 4para-methoxymethamphetamine, PMMA) 12455(e) Any material, compound, mixture or preparation that contains any 6quantity of the following substances having a depressant effect on the 7central nervous system, including its salts, isomers, and salts of isomers 8whenever the existence of such salts, isomers, and salts of isomers is 9possible within the specific chemical designation:10(1) Etizolam 278011Some trade or other names: (4-(2-chlorophenyl)-2-ethyl-9-methyl-6H-12thieno[3,2-f][1,2,4]triazolo[4,3-a][1,4]diazepine)13(2) Mecloqualone 257214(3) Methaqualone 256515(4) Gamma hydroxybutyric acid 201016(5) 8-chloro-6-(2-fluorophenyl)-1-methyl-4H-benzo[f]17[1,2,4]triazolo[4,3-a][1,4]diazepine, its salts, isomers, and salts of isomers18 (other name: flualprazolam) 278519(6) 6-(2-chlorophenyl)-1-methyl-8-nitro-4H-benzo[f]20[1,2,4]triazolo[4,3-a][1,4]diazepine, its salts, isomers, and salts of isomers 21(other name: clonazolam) 278622(7) 8-bromo-6-(2-fluorophenyl)-1-methyl-4H-benzo[f]23[1,2,4]triazolo[4,3-a][1,4]diazepine, its salts, isomers, and salts of isomers24 (other name: flubromazolam) 278825(8) 7-chloro-5-(2-chlorophenyl)-1-methyl-1,3-dihydro-2H-benzo[e]26[1,4]diazepin-2-one, its salts, isomers, and salts of isomers (other name: 27diclazepam) 278928(f) Unless specifically excepted or unless listed in another schedule, 29any material, compound, mixture or preparation that contains any quantity 30of the following substances having a stimulant effect on the central 31nervous system, including its salts, isomers and salts of isomers:32(1) Aminorex 158533Some other names: Aminoxaphen 2-amino-5-phenyl-2-oxazoline or 4,5-34dihydro-5-phenyl-2-oxazolamine35(2) Fenethylline 150336(3) N-ethylamphetamine 147537(4) (+)cis-4-methylaminorex ((+)cis-4,5-dihydro-4-methyl-5-phenyl-382-oxazolamine) 159039(5) N,N-dimethylamphetamine (also known as N,N-alpha-trimethyl-40benzeneethanamine; N,N-alpha-trimethylphenethylamine) 148041(6) Cathinone (some other names: 2-amino-1-phenol-1-propanone, 42alpha-amino propiophenone, 2-amino propiophenone and norphedrone)43 12351(7) Substituted cathinones2Any compound, except bupropion or compounds listed under a different 3schedule, structurally derived from 2–aminopropan–1–one by substitution 4at the 1-position with either phenyl, naphthyl, or thiophene ring systems, 5whether or not the compound is further modified in any of the following 6ways:7 (A) By substitution in the ring system to any extent with alkyl, 8alkylenedioxy, alkoxy, haloalkyl, hydroxyl, or halide substituents, whether 9or not further substituted in the ring system by one or more other univalent 10substituents;11 (B) by substitution at the 3-position with an acyclic alkyl 12substituent;13 (C) by substitution at the 2-amino nitrogen atom with alkyl, 14dialkyl, benzyl, or methoxybenzyl groups; or15 (D) by inclusion of the 2-amino nitrogen atom in a cyclic 16structure.17(8) N-benzylpiperazine (other names: BZP, 1-benzylpiprazine)18 749319(9) Methiopropamine20(N-methyl-1-(thiophen-2-yl)propan-2-amine) 147821(10) 4,4′-Dimethylaminorex (4,4′-DMAR; 4,5-dihydro-4-methyl-5-(4-22methylphenyl)-2-oxazolamine; 4-methyl-5-(4-methylphenyl)-4,5-dihydro-231,3-oxazol-2-amine) 159524(11) Amineptine (7-[(10,11-dihydro-5 H-dibenzo[a,d]cyclohepten-5-25yl)amino]heptanoic acid) 121926(12) Mesocarb (N-phenyl-N ′-(3-(1-phenylpropan-2-yl)-1,2,3-27oxadiazol-3-ium-5-yl)carbamimidate) 122728(g) Any material, compound, mixture or preparation that contains any 29quantity of the following substances:30(1) N-[1-benzyl-4-piperidyl]-N-phenylpropanamide (benzylfentanyl), 31its optical isomers, salts and salts of isomers32(2) N-[1-(2-thienyl)methyl-4-piperidyl]-N-phenylpropanamide 33(thenylfentanyl), its optical isomers, salts and salts of isomers34(3) Tianeptine, its optical isomers, salts and salts of isomers35(h) Any of the following cannabinoids, their salts, isomers and salts 36of isomers, unless specifically excepted, whenever the existence of these 37salts, isomers and salts of isomers is possible within the specific chemical 38designation:39(1) Tetrahydrocannabinols 737040Meaning tetrahydrocannabinols naturally contained in a plant of the genus 41Cannabis (cannabis plant), as well as synthetic equivalents of the 42substances contained in the plant, or in the resinous extractives of 43Cannabis, sp. and/or synthetic substances, derivatives, and their isomers 1with similar chemical structure and pharmacological activity such as the 2following: Delta 1 cis or trans tetrahydrocannabinol, and their optical 3isomers Delta 6 cis or trans tetrahydrocannabinol, and their optical isomers 4Delta 3,4 cis or trans tetrahydrocannabinol, and its optical isomers (Since 5nomenclature of these substances is not internationally standardized, 6compounds of these structures, regardless of numerical designation of 7atomic positions covered.), except tetrahydrocannabinols in any of the 8following:9 (A) Industrial hemp, as defined in K.S.A. 2-3901, and 10amendments thereto;11 (B) solid waste, as defined in K.S.A. 65-3402, and amendments 12thereto, and hazardous waste, as defined in K.S.A. 65-3430, and 13amendments thereto, if such waste is the result of the cultivation, 14production or processing of industrial hemp, as defined in K.S.A. 2-3901, 15and amendments thereto, and such waste contains a delta-9 16tetrahydrocannabinol concentration of not more than 0.3%; or17 (C) hemp products, as defined in K.S.A. 2-3901, and amendments 18thereto, unless otherwise deemed unlawful pursuant to K.S.A. 2-3908, and 19amendments thereto.20(2) Naphthylmethylindoles21Any compound containing a 1H-indol-3-yl-(1-naphthyl)methane structure 22with substitution at the nitrogen atom of the indole group by an alkyl, 23haloalkyl, cyanoalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl, benzyl, 241-(N-methyl-2-piperidinyl)methyl or 2-(4-morpholinyl)ethyl group 25whether or not further substituted on the indole group to any extent and 26whether or not substituted on the benzyl or naphthyl ring to any extent.27(3)(2) Naphthoylpyrroles28Any compound containing a 3-(1-naphthoyl)pyrrole structure with 29substitution at the nitrogen atom of the pyrrole group by an alkyl, 30haloalkyl, cyanoalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl, benzyl, 311-(N-methyl-2-piperidinyl)methyl or 2-(4-morpholinyl)ethyl group 32whether or not further substituted on the pyrrole group to any extent, 33whether or not substituted on the benzyl or naphthyl ring to any extent.34(4)(3) Naphthylmethylindenes35Any compound containing a naphthylmethylindene structure with 36substitution at the 3-position of the indene group by an alkyl, haloalkyl, 37cyanoalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl, benzyl, 1-(N-38methyl-2-piperidinyl)methyl or 2-(4-morpholinyl)ethyl group whether or 39not further substituted on the indene group to any extent, whether or not 40substituted on the benzyl or naphthyl ring to any extent.41(5)(4) Cyclohexylphenols42Any compound containing a 2-(3-hydroxycyclohexyl)phenol structure 43with substitution at the 5-position of the phenolic ring by an alkyl, 1haloalkyl, cyanoalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl, 1-(N-2methyl-2-piperidinyl)methyl or 2-(4-morpholinyl)ethyl group whether or 3not substituted on the cyclohexyl ring to any extent.4(6)(5) 2,3-Dihydro-5-methyl-3-(4-morpholinylmethyl)pyrrolo[1,2,3-de]-51,4-benzoxazin-6-yl]-1-napthalenylmethanone.6Some trade or other names: WIN 55,212-2.7(7)(6) 9-(hydroxymethyl)-6, 6-dimethyl-3-(2-methyloctan-2-yl)-86a,7,10,10a-tetrahydrobenzo[c]chromen-1-ol9Some trade or other names: HU-210, HU-211.10(8)(7) Indole-3-carboxylate esters11Any compound containing a 1H-indole-3-carboxylate ester structure with 12the ester oxygen bearing a naphthyl, quinolinyl, isoquinolinyl or 13adamantyl group and substitution at the 1 position of the indole ring by an 14alkyl, haloalkyl, cyanoalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl, 15benzyl, 1-(N-methyl-2-piperidinyl)methyl or 2-(4-morpholinyl)ethyl 16group, whether or not further substituted on the indole ring to any extent 17and whether or not substituted on the naphthyl, quinolinyl, isoquinolinyl, 18adamantyl or benzyl groups to any extent.19(9)(8) Indazole-3-carboxamides20Any compound containing a 1H-indazole-3-carboxamide structure with 21substitution at the nitrogen of the carboxamide by a naphthyl, quinolinyl, 22isoquinolinyl, adamantyl, benzyl, 1-amino-1-oxoalkan-2-yl or 1-alkoxy-1-23oxoalkan-2-yl group and substitution at the 1 position of the indazole ring 24by an alkyl, haloalkyl, cyanoalkyl, alkenyl, cycloalkylmethyl, 25cycloalkylethyl, benzyl, 1-(N-methyl-2-piperidinyl)methyl, or 2-(4-26morpholinyl)ethyl group, whether or not further substituted on the 27indazole ring to any extent and whether or not substituted on the naphthyl, 28quinolinyl, isoquinolinyl, adamantyl, 1-amino-1-oxoalkan-2-yl, 1-alkoxy-291-oxoalkan-2-yl or benzyl groups to any extent.30(10)(9) Indole-3-carboxamides31Any compound containing a 1H-indole-3-carboxamide structure with 32substitution at the nitrogen of the carboxamide by a naphthyl, quinolinyl, 33isoquinolinyl, adamantyl, benzyl, 1-amino-1-oxoalkan-2-yl or 1-alkoxy-1-34oxoalkan-2-yl group and substitution at the 1 position of the indole ring by 35an alkyl, haloalkyl, cyanoalkyl, alkenyl, cycloalkylmethyl, 36cycloalkylethyl, benzyl, 1-(N-methyl-2-piperidinyl)methyl, or 2-(4-37morpholinyl)ethyl group, whether or not further substituted on the indole 38ring to any extent and whether or not further substituted on the naphthyl, 39quinolinyl, isoquinolinyl, adamantyl, 1-amino-1-oxoalkan-2-yl, 1-alkoxy-401-oxoalkan-2-yl or benzyl groups to any extent.41(11)(10) (1H-indazol-3-yl)methanones42Any compound containing a (1H-indazol-3-yl)methanone structure with 43the carbonyl carbon bearing a naphthyl group and substitution at the 1 1position of the indazole ring by an alkyl, haloalkyl, alkenyl, 2cycloalkylmethyl, cycloalkylethyl, benzyl, 1-(N-methyl-2-3piperidinyl)methyl, or 2-(4-morpholinyl)ethyl group, whether or not 4further substituted on the indazole ring to any extent and whether or not 5substituted on the naphthyl or benzyl groups to any extent.6(12)(11) (1H-indol-3-yl)methanones7Any compound containing a (1H-indol-3-yl)methanone structure with the 8carbonyl carbon bearing a naphthyl, quinolinyl, isoquinolinyl, adamantyl, 9phenyl, benzyl or tetramethylcyclopropyl group and substitution at the 1 10position of the indole ring by an alkyl,haloalkyl, cyanoalkyl, alkenyl, 11cycloalkylmethyl, cycloalkylethyl, benzyl, 1-(N-methyl-2-12piperidinyl)methyl, 2-(4-morpholinyl)ethyl, 1-(N-methyl-2-13pyrrolidinyl)methyl, 1-(N-methyl-3-morpholinyl)methyl, or 14tetrahydropyranylmethyl group, whether or not further substituted on the 15indole ring to any extent and whether or not substituted on the naphthyl, 16quinolinyl, isoquinolinyl, adamantyl, phenyl, benzyl or 17tetramethylcyclopropyl groups to any extent.18Sec. 19. K.S.A. 21-5706 and 21-5709 and K.S.A. 2025 Supp. 21-195701, 21-5705, 65-4101 and 65-4105 are hereby repealed.20Sec. 20. This act shall take effect and be in force from and after its 21publication in the statute book. search keyboard_arrow_up keyboard_arrow_down Page 1 Page 2 Page 3 Page 4 Page 5 Page 6 Page 7 Page 8 Page 9 Page 10 Page 11 Page 12 Page 13 Page 14 Page 15 Page 16 Page 17 Page 18 Page 19 Page 20 Page 21 Page 22 Page 23 Page 24 Page 25 Page 26 Page 27 Page 28 Page 29 Page 30 Page 31 Page 32 Page 33 Page 34 Page 35 Page 36 Page 37 Page 38 Page 39 Page 40 Page 41 Page 42 Page 43 Page 44 Page 45 Page 46 Page 47 Page 48 Page 49 Page 50 Page 51 Page 52 Page 53 Page 54 Page 55 arrow_upward Top Kansas State Legislature

    300 SW 10th Ave, Topeka, KS 66612

    Ad Astra Per Aspera

    Kansas Legislative Hotline
    In-State: 1-800-432-3924
    Out-of-State: 785-296-2149

    Government

    • Legislators
    • House
    • Representatives
    • Senate
    • Senators
    • Committees

    Resources

    • Bills & Measures
    • Today
    • Live
    • Journals
    • Calendars
    • Archived Records
    • Laws
    • Search
    • RSS Feeds

    Support

    • Contact Us
    • Accessibility
    • Privacy Policy
    • Visit Us
    © 2026 Kansas State Legislature. All rights reserved. Data updated 0 minutes ago · 4:20 PM 11/14/2026

    Texto oficial de la Legislatura de Kansas. El formato se adaptó para leerlo en Ratifi.